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ABSTRACT
Microbes inhabit all parts of human body that are exposed to the environment and their
interactions with human host mutually benefit each other and play significant roles in human
health and diseases. The human gastrointestinal tract harbors the largest population of the
microbiota and has gained broad research attention and efforts over the past decade. Colonization
of the gut by microbes begins at birth and this early-life bacterial establishment can impact
infants’ health and even the human health and lifestyle across an entire life span. Recent studies
on community structure and composition of infant gut microbiota have revealed the species
shifts and variations during early bacterial colonization of the infant gut. However, little is
known about functional activities of the community and how these functions change in response
to different life events. Therefore, comprehensive proteomic characterization of the infant gut
microbiome is needed to elucidate biological activities in this complex ecosystem. In this
dissertation, we first developed a metaproteomics pipeline integrating both experimental and
informatics components with careful considerations to simultaneously access microbial and
human host proteins contained in infant fecal samples. The developed approach was applied in a
longitudinal study of a healthy premature infant gut, revealing the overall metabolic cooperation
between the human host and the gut microbiota and the temporal functional shifts in both
microbiome and corresponding host response during the colonization process. To further
investigate the commonalities and differences of gut microbiome between individuals, timeseries metaproteomic studies were performed in three more premature infants, uncovering
common core proteins/metabolic pathways established during early life microbiome
establishment, as well as unique pathways that were specific to particular infants or present in
certain colonization time period. In a broad perspective, the approaches and results presented in
iv

this dissertation have provided insights into functions and activities of human gut ecosystem, and
developed techniques and outlined general considerations that can be extended to proteome
characterization of all complex ecosystems.
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CHAPTER 1
Introduction to mass spectrometry based metaproteomic characterization of
human gut microbiome
Part of the text below was adapted from:
Weili Xiong, Paul Abraham, Zhou Li, Chongle Pan, Robert L. Hettich. Microbial
metaproteomics for characterizing the range of metabolic functions and activities of human gut
microbiota. Proteomics, 2015, 15 (20), 3424-3438.
Weili Xiong’s contributions included: literature review, manuscript writing in experimental
workflow and human gut metaproteoimcs studies sections, data analysis, and manuscript editing.

1.1 Meta-omics technologies enable microbial community functional characterization
1.1.1 Microbial community
Microorganisms constitute the largest population grouping on Earth, outnumbering all
other living organisms and constituting the main portion of the Earth’s biomass [1]. In nature,
microbes do not live in isolation, but rather function together as members of complex dynamic
communities that can range from low complexity systems in extreme environments, such as acid
mine drainage biofilm [2], to a moderate complexity of communities that inhabit in the human
body [3], to tens of thousands of species that colonize the environment ecosystems such as soils
[4] and seawaters [5]. Ubiquitous throughout the natural environment, these microorganisms
represent a remarkable biodiversity and greatly contribute to all ecosystem processes, e.g.
biogeochemical recycling of essential elements such as carbon and nitrogen [6]. In addition,
microbial communities are associated with and also directly impact other macro-organisms like
plants, animals and humans. The human body is one example of a unique ecosystem that is
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continuously inhabited by a diverse collection of microbes (including bacteria, fungi, protozoa,
viruses and archaea) [7]. The interaction between the microbiome and human host has a
profound impact upon human health and so the disruption of this intricate balance between the
microbial colonization and human host corresponding responses has been linked to a wide range
of inflammatory, metabolic, and central nerves system disorders [8-11].
Despite the tremendous success achieved by classic microbiology focusing on singleprotein study and pure-culture isolate investigation, the major challenge in modern microbial
physiology and ecology is to globally understand microbial community composition, structure,
function and most importantly, how microbes interact in situ and respond to their environment.
The advent of comprehensive whole-genome sequencing technology [12, 13] has enormously
expanded our knowledge of microbial metabolism by revealing a complete gene inventory list
for single pure culture isolates. Nevertheless, estimates indicate that over 90% environmental
microorganisms are not cultivatable or not yet cultured [14] and the true microbial activities and
interactions in the natural environment cannot be simulated in the traditional laboratory
experiment. As a result, the field of metagenomics has developed [15, 16], where genomic
analysis of a mixed microbial community is carried out based on microbial DNA that is directly
extracted from the environmental samples, regardless of the isolation and cultivation of
microbial members.

These sequence data provide the potential function of microbial

communities and also pave the way for system biology studies employing multiple meta-omics
approaches [17]. These large-scale technologies have allowed the investigation of all the levels
of biological information (DNA, RNA, proteins and metabolites), each of which provides a
different level of insight into the complex metabolic processes and interactions contributing to
the microbial ecosystem.
2

1.1.2 Metaproteomics among various –omics technologies
“Omics” technologies offer a holistic view of all molecules in an organism or a
community. Aiming to characterize complete microbial ecosystems, four major types of highthroughput measurements are commonly employed: metagenomics (DNA), metatranscriptomics
(RNA), metaproteomics (proteins) and meta-metabolomics (metabolites) (Figure 1.1). Since
DNA carries the instruction that builds the functional biomolecules, the metagenome provides
the potential list of genes that could possibly be expressed by the communities. The
metatranscriptome reveals the transcriptionally active subset of the genomes, which provides
some information about the gene expression and regulation at the time of sampling. Primarily
responsible for structural and enzymatic activities, proteins reflect dynamics and specific
microbial activities in a given environment, making metaproteomics a particularly useful tool for
the characterization of the microbial functionality. Additionally, the meta-metabolome reveals
small molecules, which can be substrates, inhibitors or products that participate in the metabolic
network and, together with the metagenome and the metaproteome, provides a strong insight into
the microbial interaction and activities. In total, these omics technologies have revolutionized
microbial ecological studies, in the way that they enable in-depth and high throughput
measurement and drastically expand our understanding of community structure, function and
dynamics in situ.
Significant advances in sequencing technologies and bioinformatics over the past decade
have created new ways to characterize the genetic repertoire of many types of environmental
communities, including microorganisms inhabiting the human body [10]. However, compared to
single isolate genome sequencing, metagenomics studies face major challenges in obtaining
deeper sequencing measurement and developing computational tools for intensive analysis [18].
3

Figure 1.1. “Multi-omics” approaches enabling the comprehensive understanding of biological ecosystems. Each level of information
(DNA, RNA, protein and metabolites) achieved by “multi-omics” approaches provides a different insight into the metabolic processes
of microbial ecosystems.
4

The complexity of communities increases not only in the number of membership, but also the
range of relative abundance of all organisms. Therefore, complete genome reconstruction
requires higher sequence coverage and more extensive assembly/curation processes. Although
different sequencing approaches have been applied to complex communities, the most commonly
used technology such as Illumina sequencing, still generates short-length reads, which make the
metagenome assembly particularly challenging, due to the repeated regions and homologous
sequences derived from closely related species [19]. In particular, low abundance genomes and
less sequenced fragments are less likely to be recovered from the metagenomics data. Although
new sequencing technologies generating longer reads or combining multiple sequencing
approaches begin to appear, it still remains to be seen what impact they will have on
metagenomics for complex microbial communities. In order to reconstruct single genomes from
metagenomics data, binning algorithms have been specifically developed for metagenomics
reads or assembled contiguous sequences (contigs). For example, one of the most widely used
binning approaches is ESOM (Emergent Self - Organizing Map), which bins assembled contigs
based on tetra - nucleotide frequencies [20] or time series abundance profiles [21]. Further
functional annotation, taxonomic classification as well as extensive curation of the genome are
required, in order to access the taxonomic information and genetic functional profiles of
microbial communities. Overall, metagenomics has become a powerful tool for microbial
community characterization, and has also provided reference information for metatranscriptomic
data mapping and metaproteomic data matching. While metagenomics reveals the potentially
expressed gene in the community, metatranscriptomics can be used to examine changes in gene
expression. Next generation sequencing (NGS) has facilitated sequencing of all populations of
RNA (termed RNAseq [22]), including messenger RNA (mRNA) and other non-coding RNAs.
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As non-coding RNAs account for 95-98% of total RNAs [23], metatranscriptomics [24]
commonly involves mRNA enrichment procedures and followed by reverse transcription to
cDNA, which can be sequenced using the same technologies as for metagenomics.
Transcriptomic reads can be mapped to assembled genomic sequences or assembled de novo for
transcript reconstruction and quantification. As mRNAs cannot account for post-translational
regulation and indeed not all mRNAs can be transcribed to proteins, transcriptome cannot be
used as a direct proxy for metabolic activities but only reflects gene expression and potential
functions.
Metaproteomics [25] aims to investigate the actual gene translational products, proteins,
in a community and provides additional information about post-translational modifications and
localization information over transcriptome measurements. The correlation between mRNA and
protein levels is generally poor at a single time snapshot, suggesting that proteome is likely more
indicative of biological phenotype than transcriptome. Commonly, metaproteomic studies
identify proteins via multi-dimensional chromatography – tandem mass spectrometry (MS/MS).
The relative protein abundance can be determined by label free, metabolic labeling and isobaric
chemical labeling approaches [26, 27]. Unlike DNA and mRNA, there is no polymerase chain
reaction (PCR) amplification for proteins and therefore it is more challenging to achieve similar
dynamic ranges in proteome measurement as that in genome and transcriptome measurement.
Although peptide sequences can be determined de novo, this strategy is rarely applied to
metaproteomic studies. Database searching is the more conventional way of peptide/protein
identifications, in which experimental MS/MS spectra are correlated against the theoretical
spectra that are derived from an available metagenome. Therefore, the success of
metaproteomics is strongly dependent on the complexity and quality of the metagenomics data.
6

In combination with metagenomics, remarkable success in metaproteomics has been
demonstrated for a variety of environmental samples [27]. Conversely, proteomic information
can also be applied to improve genome annotation [28]. The advantage of metaproteomics over
other omics technology is that identified proteins can be directly used for active pathway and
metabolic function construction and specific functions can be further attributed to different
species in the community.
Even though metaproteomics is a powerful tool to interrogate microbial function in the
ecosystem, protein abundance cannot accurately predict a protein’s activity or functional state.
To achieve a more complete understanding of metabolic activities, meta-metabolonmics usually
complements metaproteomics by providing information of small molecule metabolites
(substrates, intermediates, end-products) involved in the metabolism [29]. It is recognized that
metabolomics provides unique insight into metabolic dynamics and characterizes the ecosystem
phenotype that results from the interplay between genomes and the environment [30]. The main
challenge of metabolomics is the ability to identify and quantify the entire set of metabolites with
diverse chemical properties [31]. In addition, their concentration and composition vary rapidly in
response to environmental changes. Thus, various extraction methods and analytical approaches
are desired, in order to capture all different compounds in the community. Unlike other omics
technologies, metabolomics is not directly linked to the genome, which makes the identification
of metabolites more challenging and impossible to assign specific taxa to any metabolites.
Indeed, most of current meta-metabolomics studies still catalog metabolite features defined by
m/z and retention time, with large amount of which are classified as unknown [32, 33].
Although above omics technologies generally measures and characterizes the gene
expression event, there are dramatic temporal information differences in these omics
7

measurements due to different half-lives and post machinery, and thus, no exact quantitative
correlation should be expected among them. In fact, each omics technology provides a unique
perspective; by integrating all these information in the cascade from genes to proteins and further
to metabolites, it is powerful to provide new insight into overall community metabolism at a
resolution and range not previously possible.

1.2 Mass spectrometry (MS) based proteomics and metaproteomics
The first proteome measurement was achieved by using two-dimensional polyacrylamide
gel electrophoresis (2D-PAGE) [34, 35], which separates proteins by isoelectric point and
protein mass. However, this technology was limited to low-complexity protein mixtures and
suffered from a lack of reproducibility and methods for identifying proteins from gel spots. In
attempt to obtain comprehensive protein identifications from complex samples, high throughput
screening, large dynamic range and accurate protein identifications are required for the
proteomic measurements. In this regard, mass spectrometry (MS) based proteomics has become
the dominant and indispensable tool for the proteomics study. The implement of mass
spectrometry in the proteome analysis was driven by the breakthrough of two soft ionization
methods: electrospray ionization (ESI) [36] and matrix assisted laser desorption/ionization
(MALDI) [37], which solved the difficulty of producing gas-phase ions from large biologically
important molecules, for example, proteins and peptides. This groundbreaking invention brought
a whole new dimension to proteomics and also led to the rapid development of protein separation
techniques and mass spectrometer instrumentation that are compatible with either ion source. To
reduce the complexity of peptide mixtures, early proteomics studies employed 2-dimensional gel
electrophoresis (2DGE) for protein separation and effectively differentiate protein isoforms and
8

modifications [38]. However, it suffered from limited dynamic range and low-throughput, and
was outperformed by liquid chromatography (LC)-based separation, which could be easily
coupled on-line with ESI-MS and enabled protein characterization of complex samples [39, 40].
At the same time, tremendous advancement in mass spectrometers, for example the advent of the
Orbitrap mass analyzer [41], has greatly increased the sensitivity, mass accuracy, dynamic range,
resolution, and scanning speed of MS measurements, and thereby leading the field towards more
advanced proteomic measurements.
As the MS platform continuously improved, two fundamental and complementary
strategies for protein identification and characterization have been established in proteomics:
top-down (TD) and bottom-up (BU) mass spectrometry (Figure 1.2) [42, 43]. The TD approach
has merged as an essential tool for protein characterization by not only offering the ability to
sequence and quantify intact proteins, but also giving the opportunity to study protein isoforms,
protein structure and post-translational modification. However, TD approach is still challenged
by the difficulty in measuring protein molecules with high molecular weight and the insufficient
separation of complex protein mixtures prior to the MS analysis [44]. As a more favorable
approach for large-scale proteomic investigations, BU proteomics, also termed as “shotgun”
proteomics, measures proteolytic peptides digested from proteins. In this method, proteins are
digested into small peptides very specifically by proteases (eg. trypsin, chymotrypsin, pepsin,
etc). Then the peptide mixture is separated by LC and subjected to MS where they are measured
by mass and further fragmented into MS/MS spectra. Bioinformatics algorithms have been
developed to assign resulting MS/MS spectra into peptides and assemble the assigned peptides
into proteins for identifications [45, 46]. Although the peptide-centric strategy is capable of
providing massive amount of information, protein identification and quantification can be
9

Figure 1.2. Top down and bottom up mass spectrometry. The top-down approach measures intact
proteins that are separated/fractionated before MS analysis. The bottom-up approach measures
proteolytic peptides digested from proteins and protein identification is achieved from peptide
sequences.
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ambiguous due to the genome redundancy and sequence homology among different proteins,
especially for high order organisms, such as human and plant. Nevertheless, BU proteomics is
currently the mainstream method for comprehensive proteomic characterization of many
biological systems. Advancement in DNA sequencing methods, LC separation and high
resolution mass spectrometry has allowed the transition of shotgun proteomics from profiling
single organism grown in culture to metaproteomics that investigates environmental
communities directly obtained in nature [47-50].
Metaproteomics, proposed by Wilmes and Bond, was first demonstrated in microbial
communities collected from acid mine drainage (AMD) site [48]. As a low complexity
ecosystem, greater than 2000 proteins were characterized in the five most abundant species from
this extreme environment. Later, the platform has been successfully applied to much more
complex ecosystems such as human gut microbiome with a thousand species of bacteria [51] and
soils comprising tens of thousands to millions of microbial species [52]. Despite the remarkable
progress that has been made in metaproteomics methods, notable challenges still remain in all
aspects of sample preparation, mass spectrometer performance and informatics tools. While
protein extraction is straightforward when applied to cultured microbial isolates, environmental
samples usually face problems with limited amount of biomass and the presence of interference
material, which prevents efficient cell lysis and protein extraction from environmental samples.
Therefore, investigators continue to develop and optimize protein extraction protocols adapting
to different types of complex samples, aiming to achieve comprehensive protein identifications
[53]. Another challenge that remains is the large dynamic range within complex samples. It
limits the detection of low abundance proteins and thus impedes the unbiased interrogation of the
entire protein complement. In order to increase the dynamic range, improvements have been
11

made in the peptide separation, for example the multidimensional protein identification
technology (MudPIT) [54]. Also, developments of high resolution, high speed mass
spectrometers, for example, the Orbitrap-Elite, have greatly increased the sampling depth and the
dynamic range of metaproteomics [55]. While experimental and technical advancements
generate more comprehensive dataset, the success of metaproteomic investigation also relies on
the quality of metagenome and informatics workflows that are compatible with large
environmental dataset. Due to the large size of the database, metaproteomics study is hindered by
computationally intensive analysis of large volume of the data, the ineffectiveness of evaluating
protein identifications using false discovery rates (FDRs), the ambiguity of protein inference and
quantification, and the inaccuracy of functional annotation and interpretation [56]. Overall, there
is a strong need for a metaproteomics pipeline that takes into accounts both experimental and
informatics complications described above, to improve the metaproteomic characterization of
environmental communities. A general informatics workflow will be further discussed in
Chapter 4.

1.3 Metaproteomics of human gut microbiome
1.3.1 Introduction to human microbiome
As one of the unique environmental communities, the human body is a complex and
dynamic ecosystem where human host and microbes live in symbiosis and together play an
important role in human physiology. There are more than 100 trillion microbial cells residing in
the human body, such as skin, oral cavity, gastrointestinal tract and vagina, which outnumber
human cells by 10 to 1 and collectively constitute our microbiome [57]. As technologies for
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sequencing and bioinformatics continue to develop, microbial structure and functional potential
of the microbiota have been revealed in different sites of the human body [58]. Substantial
variations have been displayed in intra-individual microbiomes at different body sites as well as
inter-individual microbiomes at the same sites across different people [59]. However,
microbiomes seem to be temporally stable and highly resilient at the same site of a single human
adult. In other words, body site is a more determinant factor than the temporal variation, unless
there is a large perturbation such as infection, or use of antibiotics that could completely change
the community structure [60]. Current research interests therefore focus on discovering different
patterns of microbiomes in healthy versus diseased states and temporally how microbial
composition changes during the course of the disease [61, 62].
The largest microbiome locates in our gastrointestinal (GI) tract ecosystem, which is
inhabited by trillions of microbes, representing thousands of bacterial species [63]. Gut
microbiota play an essential role in human health and diseases by processing and providing
human host essential nutrients, acting as a barrier to prevent the pathogen invasion and aiding in
the establishment and development of human immune system [64]. For example, intestinal
microbes contribute to the degradation of certain food components such as planted-derived
polysaccharides, production of short chain fatty acids (SCFA) such as acetate, propionate and
butyrate, and synthesis of vitamins that are essential to human health. Indeed, a balance between
the microbial colonization and human host responses is crucial to the maintenance of human
health. However, to date, relatively little is known about the intricate details and balance of the
human gut microbiota.
As studied over the past decade, intestinal microbiota can be impacted by host genetics,
environmental factors, types of diets and health status [65-68]. For example, a recent study
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identified microbial taxa whose abundances were more similar in monozyotic twins as compared
to dizygotic twins [65]. Studies on obesity have revealed that dietary interventions could change
some individual’s microbiota [69]. Also, the dysfunction of microbiota has been linked with a
large number of diseases such as obesity and Crohn’s disease [3, 70, 71]. Given that not a single
organism but rather community characteristics are more associated with diseases, the
metaproteomic characterization of functional activities and interactions for gut microbiota will
be central to our understanding of microbiome in relation to diseases.
1.3.2 Current human gut metaproteome studies
So far, relatively few studies have been conducted on the gut microbial metaproteome, in
spite of large numbers of metagenomic interrogations. This is due at least in part by several
challenges in gut proteome studies: 1) heterogeneity of bacterial species composition among
different individuals; 2) wide dynamic range of protein abundances, especially dominant human
proteins that mask the low abundance microbial microbiome; 3) lack of matched metagenomes
or low quality metagenome assemblies/annotations that impede comprehensive MS/MS
spectrum assignment; 4) informatics hurdles, such as differentiation and quantification of
proteins from closely related species and characterization of diverse post-transcriptional
modification events. In the following section, we will briefly highlight the range of human gut
metaproteomics studies published to date, and how the information they provide is helping to
shape our understanding of this unique ecosystem, and its effect on health vs. disease.
1.3.2.1 Insights into the stable microbiome of a healthy human adult gut
The first metaproteomic study of an adult human gut microbiota was performed on a
healthy female monozygotic twin pair from a Swedish twin cohort [72]. Thousands of identified
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proteins facilitated the first glimpse of the functional signature of the human gut microbiome,
providing insight into the host-bacterial interaction in the gastrointestinal tract. Expectedly, a
substantial proportion of the proteins identified in the samples (30%) were human proteins,
including but not limited to the functional categories humane innate immunity, cell-to-cell
adhesion, and digestion enzymes. Notably, most of the relatively abundant human proteins were
similar among the two individuals, yet some differences were found in less abundant proteins,
which can be expected due to the stochastic sampling nature of the approach.
A high-level overview of biological processes occurring in gut microbiota was obtained
by cataloging identified proteins by Cluster of Orthologous Groups (COGs) [73]. An uneven
distribution of relative abundances of each COG in the identified metaproteome relative to
metagenome was revealed [72]: the metaproteome was enriched in proteins involved in
translation, energy production, and carbohydrate metabolism, whereas the metagenome was
dominated by proteins involved in inorganic ion metabolism, cell wall and membrane biogenesis,
cell division, and secondary metabolite biosynthesis. Although there are clearly measurement
depth differences between these datasets, these observational differences emphasize the
important point that in situ functional activities (as measured by the metaproteome) can be
significantly distinct from what is predicted from the metagenome information alone.
1.3.2.2 Microbial functional divergence of healthy versus disease state

The first comparison of the intestinal microbiota between healthy and diseased adults
focused on Crohn’s disease (CD) [10]. In brief, CD is an inflammatory bowel disease with
evidence converging to suggest that imbalance in the microbiota plays a central role in chronic
inflammation associated with CD. In contrast to the healthy twin pair described above, five other

15

twin pairs were selected here, including one concordant colonic CD (CCD) twin pair, two
concordant ileum CD (ICD) twins, and two discordant ICD twins were analyzed. Due to
advancements in protein sequencing technology as well as sample preparation, this study was
able to achieve a more detailed investigation into the presence of microbial and human proteins,
identifying 4,120 microbial protein groups and 1,646 human proteins. With a comprehensive
cataloging of proteins and their relative abundances across the individuals, this study highlighted
key functional signatures of CD, which were associated with alterations in bacterial metabolism
(e.g. deficiency in general processes, depleted enzymes for carbohydrates and mucin degradation,
and depletion of butyrate and other short-chain fatty acids), bacterial-host interactions (e.g.
higher expression of bacterial outer membrane proteins that participate in inflammatory immune
responses), and host corresponding response (e.g. impaired epithelial barrier and high abundance
of pancreatic enzymes). Consistent with previous 16S rRNA-based phylogenetic analysis and
metabolite analysis of the same cohort, the measured metaproteomes clustered according to
individuals’ disease status, rather than host genetics. Additionally, reduced protein abundances
for butyrate production and degradation of mucin from beneficial bacteria were in agreement
with the decreased abundances of these species revealed from previous 16S based phylogenetic
profiling. Overall, this study revealed a catalogue of proteins exhibiting the functional signatures
of the disease and therefore provided potential targets for future diagnostic and therapeutic
research.
In a more targeted investigation, a recent cross-sectional study conducted on six CD
patients and six healthy controls also characterized protein signals associated with CD [74]. A
subset of 13 candidate proteins was selected and confirmed by selected reaction monitoring
(SRM). 12 bacterial proteins mainly derived from Bacteroides were strongly linked to CD, as
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well as one depleted human glycoprotein 2 of zymogen granule membranes (GP2), which may
promote bacteria binding to host cell receptors and induce inflammatory responses. In total, this
study not only discovered but also confirmed and quantified a list of CD-associated microbial
proteins, which can serve as candidate targets for IBD treatment.
In effort to identify how the gut microbiota contributes to obesity, Ferrer et al. performed
comparative metagenomics and metaproteomics of human fecal samples from one ‘lean’ and one
‘obese’ adolescent [75]. In brief, the proteins identified by shotgun proteomics revealed a drastic
change in the total and functionally active microbial community; Bacteroidetes represented the
most functional bacteria (81% of total protein) in the lean gut, whereas the obese gut had
relatively equal abundances of Firmicutes and Bacteroidetes proteins. This observation is
consistent other studies that have shown that the relative abundance of Bacteroidetes increases as
obese individuals lose weight [76]. Overall, this study highlighted the importance of comparative
metaproteomics approaches to further our understanding of the functional changes that occur in
response to obesity.
1.3.2.3 Longitudinal changes and shifts in microbiota functionality

To date, only two studies have examined the change of adult gut metaproteomes as a
function of time. In the first study, the metaproteomes of three healthy, omnivorous female
subjects were characterized twice within a year [77]. As a novel finding, the fecal metaproteome
of each individual was relatively stable during one year period, despite distinct inter-individual
differences. In addition, approximately 1,000 proteins were observed in all subjects and likely
represent core functional categories, which were also highly representative in other intestinal
metaproteome studies [72]. These observations suggested a presumable common functional core
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in healthy individuals, which is mainly involved in carbohydrate transport and degradation as
well as a variety of surface proteins reflecting bacterial adaption to the intestinal environment. A
later time-series study examined gut microbial communities over multiple time points from an
individual before and after antibiotic (AB) treatment [78]. Based on integrated multi-omics data,
the study proposed a presumptive model describing temporal responses of intestinal microbiota
to AB therapy, from the perspective of microbial composition dynamics and metabolic activity
regulation.
1.3.2.4 The mucosal luminal interface (MLI)
In general, the intestinal mucosal surface is a barrier layer that prevents the invasion of
pathogens and mediates most interactions between the host and luminal intestinal microbiota.
Thus far, two studies have profiled MLI metaproteomes in mucosal lavage samples. The first
study analyzed 205 lavage samples from six colon regions of 38 healthy subjects [79]. The
results were compared with mucosal biopsy transcriptome and showed enrichment in
extracellular proteins involved in immune response. Also, metaproteomes from 6 colon regions
were further compared, revealing biogeographic features of MLI metaproteome with distinct
differences between the proximal colon and the distal colon. The second study investigated the
bacteria and metaproteome at the MLI of CD, ulcerative colitis, and healthy subjects, and
identified five bacterial phylotypes and a large number of proteins associated with the
inflammatory bowel disease (IBD) [80]. Moreover, the relationship between bacteria and
metaproteome provided a correlation that could be used to sort most subjects by disease type,
supporting the potential role of host-microbe interaction in the etiology of IBD. Investigating the
metaproteome of the MLI provides an additional dimension to the characterization of host-
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microbial interaction, because the approach is capable of analyzing the biogeographic-specific
metaproteomes at different locations along the gastrointestinal tract.
The two studies outlined above provide evidence that the bacteria and proteins identified
in MLI are clearly involved in host-microbe interactions, which are potentially critical for
disease biology. In a somewhat distinct but complementary fashion, fecal microbiota
undoubtedly represent a mixture of species from various intestinal regions, thereby presenting an
average but broader picture of all microbes and their functional activities along the human gut.
Altogether, microbiome studies focused on both fecal and mucosal materials can be
complementary to more fully characterize the functions of gut microbiota in human physiology.
1.3.2.5 Model gut microbiome systems in gnotobiotic animals
Gnotobiotic mice can be custom-designed with a defined microbial membership and
therefore provide a tractable in vivo model to study bacterial and host dynamics. In fact, the
microbiome can be ‘humanized’ by inoculating the germ-free gnotobiotic mice with a defined
collection of human gut members. For example, to study the adaption of dietary Lactococcus
lactis to the digestive tract, Roy et al. colonized gnotobiotic mice with a Lactococcus lactis strain
and then analyzed the metaproteomes of fecal and cecal samples [81]. Although increased
GroEL expression in fecal samples suggested that the bacteria were adapting to dehydrated
environment in the colon, nearly identical protein profiles were identified between bacteria from
feces and cecum. As compared to proteins from in vitro culture, the in vivo proteome showed
activation of pathways involved in carbon source assimilation, pyruvate catabolism and pentose
phosphate, reflecting changes in the fermentative metabolism of L. lactis in the digestive
environment. A similar study on the proteome of commensal E. coli in a gnotobiotic mouse was
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later performed [82]. In this case, E. coli appeared to express proteins/enzymes that facilitate the
utilization of a variety of carbohydrates and amino acids present in the intestinal tract.
Gnotobiotic mice have also been employed to better understand colonization and
microbial interactions in the host gut. For example, a model two-member human gut microbiome
consisting of E. rectale and B. thetaiotaomicron was created in gnotobiotic mice to study how
they interact and respond to host diet [83]. The study mainly focused on the transcriptomic
changes after colonization, but proteins present in luminal contents were also analyzed by highresolution mass spectrometry. In general, the proteome datasets were complementary to the
transcriptome information, and revealed proteins abundant in both microbes as ribosomal
proteins, elongation factors, chaperones, and proteins involved in energy metabolism.
Moving beyond a two-member community, a higher level of microbial complexity was
evaluated by colonizing gnotobiotic mice with a model human gut microbiota comprising 12
human gut bacterial species and feeding them with high-fat vs. low-fat diets [84]. Importantly, as
the complexity of the metaproteome increased, the assignment of peptides unique to proteins was
affected by homologous proteins and closely related species. Furthermore, the correlation
between mRNA and protein data was evaluated for Bacteroides cellulosilyticus WH2 genes
revealed a moderate correlation (r =0.53) between overall mRNA and protein levels; yet, the
correlations of genes in different functional categories were significantly different. For example,
genes involved in translation showed no correlation whereas genes predicted in carbohydrate
metabolism had a strong correlation between RNA and protein observations. This further
emphasizes the significance of proteome measurement because proteins represent actual
functional molecules that may have different temporal and stability characteristics compared
with their corresponding transcripts.
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The development of “humanized” gut microbiomes in gnotobiotic animals provides a
unique ecosystem in which microbial membership can be carefully designed (to control
complexity), controlled, and manipulated in a systematic fashion that is not possible in human
subject studies. Clearly, the eukaryotic host differences are important here as well, but this
system is becoming increasingly important for sorting out and simplifying the complex variables
present in human systems.
1.3.2.6 Human infant gut metaproteome
Compared to the adult gut microbiota, the human infant gut has been much less studied.
While the variability of the human gut microbiota is astounding, it is not unexpected, given the
influences from genetic variation and diverse cultural environments. Although the human infant
gut is thought to be generally sterile at birth, this theory has been recently challenged by new
evidence suggesting the presence of microbes in amniotic fluid, placenta, and the infant’s
meconium [85-87]. Following birth, rapid microbial colonization occurs and, for the next few
years, the microbial composition continues to undergo dramatic changes until a stable microbiota
is established [88]. As such, the early microbial composition of the infant gut is relatively simple
and of low complexity, and therefore poses fewer analytical challenges (e.g., sampling depth)
than the richer, more diverse microbial communities evident in the adult human gut. However,
with increasing time, the microbial composition varies tremendously, even from week to week,
and therefore a comprehensive profiling of the infant gut requires a greater number of sampling
points to effectively capture this inherent variation across time.
Emerging evidence has suggested that not only does the initial colonization of the
gastrointestinal tract play a critical role in the development of a stable, healthy ‘adult’ microbiota,
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but also that deviations from the native early-life bacterial establishment can impact human
health and lifestyle across an entire life span [89, 90]. For example, one of the most devastating
conditions of premature infants is necrotizing enterocolitis (NEC), which affects 10% of
premature infants and has a mortality rate of 30% - 50% [91]. NEC typically develops within the
first 2 weeks after birth and once developed, the progression is rapid with significant clinical
consequences. NEC is often incurable, and those who survive can suffer from long-term
complications such as intestinal stricture and short-gut syndrome [92]. The specific pathogenesis
of NEC is still unknown, but factors involved in prematurity, low birth weight, feeding type, use
of antibiotics and intestinal bacterial colonization have been indicated in the etiology of NEC [93,
94]. Given the findings that NEC does not occur in germ – free animals [95] and outbreak of
NEC could occur in multiple neonates [96], the pattern of microbial community remains to be
the most important target in the pathogenesis of NEC. As compared to term infants, premature
infants typically harbor delayed and less complex microbial communities. However, no single
species or microbial pattern has been identified as infectious agents [97], suggesting that
microbial activities, or interactions among microbes and between microbes and human host may
contribute to the onset of NEC. Therefore, it is of great interests to not only capture the genetic
diversity of the infant gut microbiome, but to also identify which genetic and external factors
alter the molecular composition and activity of the infant gut microbiome.
Although the human infant gut microbiome is a logical place to begin metaproteome
studies, to date there have been very little published in this arena. Despite having limited genome
information, Klaassens et al. reported the first attempt to use a metaproteomics approach to
functionally characterize microbial protein composition changes over time in a human infant
fecal sample [98]. Although the level of protein identification was severely limited in this study,
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this report revealed the need for enhanced experimental (sample preparation as well as
measurement methods) and informatics (in particular, more detailed and accurate metagenomes)
methodologies. Our understanding of the infant microbiome has since broadened, in part owing
to the tremendous improvements in DNA and protein sequencing technologies, as well as
significant advancements in the bioinformatic tools used to assemble, annotate, and analyze the
data generated. In a more recent study, Young et al. achieved a more comprehensive
metaproteome analysis of the infant gut microbiome, providing a rich dataset that has led to a
better understanding of the dynamic changes in the functional signature of the infant microbiome
[99]. For example, this study demonstrated that the functional signature of the microbial
community increased in complexity within 2-3 weeks, stabilized relatively early, and remained
remarkably conserved thereafter. Additionally, several microbial-related human proteins were
concomitantly observed. In particular, several innate immunity proteins in the same fecal
samples revealed a level of human host - microbiome cross-talk.

1.4 Scope of the dissertation
This dissertation focuses on the development and application of a high performance mass
spectrometry and computational informatics platform for human gut microbiome research. In
particular, the research presented in this dissertation aims to measure thousands of proteins from
infant gut microbiome samples, in an effort to understand metabolic activities of both human
host and microbial membership during early life microbial colonization of healthy and diseased
premature infants. This field is still in its infancy and thus this dissertation characterizes the
infant gut metaproteome with following objectives: 1) optimize the experimental methodology
and MS platforms to enhance the depth of infant gut metaproteome measurement; 2) design a
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bioinformatics workflow for searching large experimental datasets with sequenced metagenome
and assembling assigned peptides into definitive protein information and 3) reveal functional
information and temporal functionality variation in the gut metaproteome among multiple infants.
Chapter 2 will provide a metaproteomics pipeline designed for human gut metaproteome
characterization with details in sample preparation methods, experimental procedures and
informatics tools for protein identifications. Chapter 3 will describe the development of an
optimized sample preparation method to fractionate human and microbial proteins in infant fecal
samples, as a more comprehensive way to improve the infant gut microbiome characterization.
Chapter 4 will focus on informatics considerations and workflow for metaproteomics, including
the discussion of evaluating the quality of assembled metagenome, protein clustering and
strategies for protein quantifications. Chapter 5 will perform a time-series metaproteomic
analysis in a healthy premature infant and reveal temporal functionality development and host
response during early life microbial colonization. Chapter 6 will include three more infants with
different health status and discuss changes of functionality in both human and microbial proteins
across time among different infants. Chapter 7 will conclude the research presented in this
dissertation and summarize the contributions of this dissertation to the human gut microbiome
field as well as future directions.
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CHAPTER 2
Experimental and computational platform for human gut microbiome
research
Part of the text below was adapted from:
Weili Xiong, Paul Abraham, Zhou Li, Chongle Pan, Robert L. Hettich. Microbial
metaproteomics for characterizing the range of metabolic functions and activities of human gut
microbiota. Proteomics, 2015, 15 (20), 3424-3438.
Weili Xiong’s contributions included: literature review, manuscript writing in experimental
workflow and human gut metaproteoimcs studies sections, data analysis, and manuscript editing.

2.1 General workflow for metaproteome measurements of human gut microbiome
The shotgun proteomics approach via 2-dimensional liquid chromatography coupled with
nano-electrospray tandem mass spectrometry (2D-LC-nESI-MS/MS) was employed for all
metaproteome experiments discussed throughout this dissertation (Figure 2.1). Since the
objective of this dissertation is to characterize the infant gut metaproteome, the general strategy
begins with the sample collection of stool samples over a specific time period from multiple
premature infants. Efficient protein extraction from environmental samples is not trivial, due to
many different interfering materials present in the sample. Thus, collected fecal samples can be
processed by direct or indirect protein extraction methods. Extracted proteins are denatured,
reduced and enzymatically digested into peptide mixtures. Prior to MS measurements, the
proteolytic peptide mixtures are separated by multidimensional high performance liquid
chromatography (HPLC), which is directly coupled with a mass spectrometer. Peptides are then
ionized and transferred into the mass analyzer and detector where their mass to charge (m/z) and
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Figure 2.1. General workflow of human infant gut metaproteomics. Protein extraction of fecal samples can be performed using a direct
or indirect method. Extracted proteins are digested into peptides, followed by liquid chromatography (LC) separation and mass
spectrometric measurements. Protein identifications are achieved by computational matching with protein database predicted from the
metagenome.
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relative abundance are measured in a full mass spectrum (MS1). For peptide sequencing, top
abundant peaks are subjected to fragmentations, generating tandem mass spectra (MS/MS). The
identification of peptides is completed by computationally matching generated experimental
MS/MS with theoretical spectra that are predicted from in silico tryptic digestion of the protein
database. This protein database is predicted and annotated based on the metagenomic sequences.
Therefore, the success of peptide identifications also relies on a high quality of metagenome
construction. Identified peptides are assembled into proteins and spectral counts or matched ion
intensity can be used for protein quantification. Overall, the pipeline presented above provides
the ability to identify and quantify thousands of proteins in complex fecal samples, and thus
characterize the infant gut microbiota functions and metabolic activities at a remarkably deep
level. Specific details for each step are discussed below.

2.2 Sample preparation
2.2.1 Sample collection
Metaproteome measurements of gut microbiota are typically conducted with fecal
samples, due in large part to the significant amount of microbial biomass in fecal material, and
the ease of collecting temporal samples that reflect intestinal conditions under either healthy or
disease-related conditions. The most common experimental challenges for this sample type
include highly abundant host cells and proteins, endogenous compounds that can interfere with
protein measurements, and limited sample sizes (e.g., human infants). In contrast to fecal
samples, other studies have used an endoscopic saline-lavage technique to study the mucosal
luminal interface (MLI) [79, 80]. Whereas fecal samples represent a mixed population of
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microbiota collected from all intestinal regions, mucosal lavage sampling profiles the microbiota
at specific biogeographic regions. These samples have been shown to yield robust recovery of
surface microbiota and often do not require any additional preprocessing besides centrifugation
to separate the cell pellet from supernatant. One potential complication of this approach is that
the collection may yield low microbial biomass, so sample handling is somewhat more difficult
and constrained.
In this dissertation, fecal samples were collected from multiple premature infants (#UN1
and #CA1 in Chapter 3, #3 in Chapter 5, #19, #21 and #23 in Chapter 6) over the first three
months. All infants were born preterm, the gestational ages of #UN1 and #CA1 are unknown and
all other infants were born at gestational age between 24 ~ 27 weeks. Detailed information about
infants is discussed in each chapter below. All samples were coded for de-identifications and
obtained under an IRB agreement protocol and sent to ORNL with dry ice by Dr. Michael
Morowitz (University of Pittsburg). Fecal samples were stored at – 80 ̊C and thawed prior to cell
lysis and protein extraction. In general, 0.3 ~ 0.5 g raw fecal material contains sufficient proteins
for proteomic measurement. Since human fecal samples are biohazards, all samples were
handled in a Biosafety Level 2 (BSL2) hood with proper personal protections.
2.2.2 Direct versus indirect sample preparation method
Depending on the focus of the study, protein extraction in fecal samples can be
accomplished by either a direct or indirect enrichment protocol. Although feces are a
complicated environmental matrix consisting of bacteria and other microbes, host cells, food
particles, and fibrous material, it is possible to extract proteins via a direct cellular lysis of raw
fecal material (typically a few grams of material), followed by protein precipitation and cleanup
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procedures [77]. A unique advantage of a direct extraction is the ability to simultaneously extract
and thus monitor both host and microbial proteins, facilitating the characterization of bacterial
signatures as well as their interplay/communication with the host. However, the depth of
microbial proteome measurement can be limited by the presence of highly abundant host
proteins, especially in infant gut samples where microbial colonization is significantly reduced.
To circumvent this challenge, indirect enrichment methods, in which bacterial cells are
separated/enriched by differential centrifugation [10, 72, 75, 78] (low speed centrifugation to
remove large fecal debris followed by high speed centrifugation to pellet bacterial cells) or highspeed centrifugation on a Nycodenz density gradient [74, 98, 100], facilitate deeper bacterial
proteome measurements, though at the expense of increased sample losses and possible sample
bias. In Chapter 3, an indirect method with double filtering strategy, which removes large fibrous
material and human cells in the first filter and then collects microbial cells in the second filter,
has developed and shown to effectively enrich microbial populations in the infant fecal samples
with dominant human proteins.
2.2.3 Cell lysis and proteome extraction
With collected cell pellets from direct or indirect method, different methods can be used
to lyse cells, including chemical (i.e., detergents, acids, alkalis or organic solvents) lysis,
mechanical (i.e., homogenization, bead-beating, sonication) disruption, or a combined approach
of both, as has been reported for proteome extraction methods from other complex media [53,
101]. While these approaches are moderately comparable in efficacy, each one has distinct
advantages and disadvantages that need to be matched to demands of the instrumentation
measurement technique employed for protein/peptide identifications.
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Recently developed SDS-TCA method has been successfully applied to efficient protein
extraction in complex environmental samples such as soil and feces [10, 53]. Sodium dodecyl
sulfate (SDS) is a strong detergent that disrupts cell membrane and denatures proteins. Due to the
presence of thick peptidoglycan layer, Gram-positive bacteria are typically less susceptible to the
detergent based cell lysis. Therefore, boiling samples in SDS followed by sonication effectively
lyse the cell and recover proteins, in particular hydrophobic proteins located in the cell
membrane. However, SDS is essentially not compatible with protease activity and MS analysis
and thus needs to be removed from protein samples. TCA (trichloroacetic acid) precipitating
proteins followed by acetone wash is frequently used to clean the sample and has shown to help
remove interfering materials such as detergents, lipids and humic acids in soil samples. Another
method, FASP (filtered – aided sample preparation) [102] employs a molecular weight cut-off
filter (typically 30 kDa) to capture proteins on the filter and wash away detergents. It performs
on-filter protein extraction and digestion, and has shown enhanced proteome results especially
for small amount of samples. However, FASP has limitations in high amount of proteins or
complex environmental samples, which can easily result in the filter clogging and failure.
Besides SDS, MS compatible detergents RapiGestTM SF (Waters) [103, 104] or sodium
deoxycholate (SDC) [105, 106] can also be used for protein extraction and show significant
advantages since they are not disruptive to protease activity and easily removed by acidification.
Nevertheless, SDS has the strongest ability to disrupt cell membrane and solubilize proteins. By
considering both the robustness and cost-effectiveness, SDS-based cell lysis followed by TCA
precipitation cleanup procedure has been applied for protein extraction in this dissertation.
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2.2.4 Protein digestion
Prior to enzymatic digestion, the total concentration of proteins was quantified using the
bichinchoninic acid (BCA) assay. This step is critical in two aspects: first, the amount of proteins
subjected to investigation can be standardized across all samples; second, an optimal amount of
protease can be applied to proteins for effective digestion. Despite many different proteases can
be used for protein digestion, trypsin is the most widely used enzyme in bottom-up proteomics.
Trypsin specifically cleaves at the C-terminal side of lysine and arginine residues (if the adjacent
amino acid is not proline), which generates tryptic peptides with average 10~15 amino acids and
positions a basic amino acid (lysine or arginine) at C terminus. In such a way, generated peptides
have a molecular weight optimal for most mass analyzers with mass range of 400 – 2,000 m/z
and carry positive charges on both ends so that peptides can be ionized and detected in the mass
spectrometer. In this study, all extracted proteins were first denatured and reduced to open up the
protein for efficient digestion. Trypsin (Promega; Madison, WI) was added in 1:100 ratio
(trypsin : protein (w/w)) according to measured protein concentration. The digestion was
performed with an initial incubation for 4 hours and followed by an additional incubation
overnight at room temperature.

2.3 Liquid chromatography
Proteolytic digestion of proteins extracted from fecal samples generally results in
complex peptide mixtures, which must then be fractionated to simplify sample complexity prior
to the mass spectrometric measurement [107]. For all proteomic experiments discussed in this
dissertation, multi-dimensional liquid chromatography separations, in specific, multidimensional
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protein identification technology (MudPIT, Figure 2.2), was used to separate the complex
peptide mixture in a high-throughput manner. MudPIT is a non-gel-based chromatography
system to resolve tens of thousands of peptides based on their charge and hydrophobicity. First
described by Yates groups, the method uses two dimensional liquid chromatography consisting
of a strong cation exchange (SCX, separating peptides by charge) and a reverse phase (RP,
separating peptides by hydrophobicity) resin in a microcapillary chromatrographic column.
In this approach, a back column was first packed with ~4 cm SCX (Luna 5 µm particle
size, 100 Å pore size, Phenomenex, Torrance, CA) followed by ~4 cm RP (C18, Aqua 5 µm
particle size, 125 Å pore size,

Phenomenex, Torrance, CA) material in a fused silica

microcapillary column (150 µm inner-diameter, Polymicro Technologies, Phoenix, AZ).
Prepared back column was pre-washed for 5 minutes with Solvent B (70% acetonitrile, 30%
HPLC grade water, 0.1% formic acid (FA)) and equilibrated for 5 minutes with Solvent A (95%
HPLC grade water, 5% acetonitrile, 0.1% FA). 25 ~ 50 µg peptides were pressure-loaded onto
the biphasic back column and bind to RP due to the hydrophobicity. Back-columns were washed
offline for 45 minutes by equilibrating with Solvent A first and eluting peptides from RP to SCX
by a gradient to Solvent B. This step is critical to the clean-up of the sample by removing the
salts or any residual SDS prior to MS measurements of the peptides. Next, the back column was
coupled in-line with a front column, which is an in-house pulled nanospray emitter (100 µm
inner-diameter, Polymicro Technologies, Phoenix, AZ). The front column was packed with ~15
cm RP material and connected to the back column via a PEEK union and 0.5 µm inline filter.
After the offline wash, the back column was coupled with a HPLC pump (U3000, Dionex,
San Francisco, CA) for liquid chromatographic separations. The assembly is provided in Figure
2.2. Solvents, including A, B (both described above), and D (500 mM ammonium acetate in
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Figure 2.2. Schematic diagram of MudPIT column setup. HPLC, high performance liquid
chromatography.
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Solvent A), flowed from the HPLC pump (µL/min) and split to either the mass spectrometer or
to the waste. This design results in a lower flow rate at the front column (nL/min) and direct the
majority of salt into the waste. The back column was connected at the first MicroTee and
directed the flow to the front column and then into the mass spectrometer. The other branch of
the first MicroTee was connected to a second MicroTee where a voltage (2-6 kV) can be applied
for the ionization process. At the end, the rest flow went into the waste through a 50 µm fused
silica providing back pressure. An appropriate length (~ 75cm) of the waste line can provide a
back pressure of ~75 bar and a flow rate of ~ 400 nL/min at the front column which aid in the
formation of electrospray.
In a MudPIT experiment, peptides were separated/eluted in 11 steps (each lasting ~2
hour) with an increasing amount of salts (ammonium acetate) followed by the RP organic
gradients in each step. During a single step, a short salt pulse (Solvent D, 5 minutes) was applied
to displace a fraction of peptides from SCX of the back column onto RP in the front column. A
long gradient (105 minutes) of increasing Solvent B from 0% to 50% was followed to further
separate the peptides in the second dimension. The concentration of salt was increased in each
iterative step from 5%, 7.5%, 10%, 12.5%, 15%, 17.5%, 20%, 25%, 35%, 50% to 100%. Only in
the last step, the gradient reaches 100% Solvent B rather than 50% in the previous 10 steps for a
complete elution of peptides. Thus at every step, only a portion of simplified peptides were
measured, and as a result, this strategy greatly improved analytical dynamic range and protein
coverage in proteomic measurements. The 11-step MudPIT was applied to proteomic
measurements in Chapter 5 and 6. A modified three-step mini MudPIT, only consists of three
salt pulses (10%, 25%, and 100% of 500 mM ammonium acetate) was employed in Chapter 3.
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2.4 Mass spectrometry instrumentation
Over the past few decades, mass spectrometry has undergone tremendous improvements
in developing and adapting various types of mass analyzers allowing for robust, accurate and
high-through proteomics experiments. A mass spectrometer typically consists of three major
components: the ionization source, the mass analyzer and the detector. The analytes of interest
are first introduced into the ionization source to produce gaseous ions with positive or negative
charges. The ions are then passed through the mass analyzer and resolved according to their mass
to charge (m/z) ratio. Ions emerging from the analyzer are detected and measured by their
relative abundance. After the signal is converted into an intensity value, the result is displayed
graphically on the computer as a mass spectrum with the relative abundance on the y-axis and
the m/z ratio on the x-axis.
2.4.1 Ionization sources
The invention of soft ionization technologies, including ESI and MALDI [36, 37], has
made possible the ionization (generally no fragmentations) of large, nonvolatile and thermally
labile biomolecules, for example peptides and proteins. These ionization methods have therefore
made mass spectrometry a popular and powerful tool for biological studies. While both methods
are widely applied in the analysis of proteins, they have distinctive but equally important features
that complement each other. In MALDI, a pulsed laser is used to desorb the analyte that has been
mixed with a matrix, promoting the ionization. MALDI has excellent sensitivity, broad mass
range and predominantly generate singly-charged ions which simplify the interpretation of
results. With all these strengths, MALDI-MS gains its high popularity in the analysis of intact
proteins with accurate molecular mass achieved. However, MALDI is incompatible with LC and
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less efficient in the fragmentation process due to the singly charged precursor ions. In contrast,
ESI generates multiply-charged ions, allowing the analysis of large molecules on limited massrange mass analyzers and facilitating more complete fragmentation spectra in tandem MS
measurements. Another important advantage of ESI over MALDI is that ESI can be easily
interfaced with LC and thus more suitable for the identification of complex peptide mixtures in a
bottom-up proteomics experiment.
ESI is conducted by applying a high voltage (typically 4 kV) to the capillary emitter that
transfers the peptide solution into the mass spectrometer (Figure 2.3). The solution moving
through the emitter is ionized into a protonated form and forms a Taylor cone (described by Sir
Geoffrey Taylor) [108] at the emitter tip where the surface tension force competes with the
electric force. When the applied voltage is high enough, the Taylor cone emits a fine jet of liquid,
which easily breaks into charged parent droplets that contain like charges (positive) distributing
across the surface of the droplet. There are two forces counterbalance each other in the droplet:
the surface tension which holds the droplet together; and the like charge repulsion (known as
Coulomb force) that tries to break down its spherical shape. As these charged droplets move
toward the heated capillary, their solvent begins to evaporate and their size shrinks. This causes
an increase of surface charge density until it reaches the “Rayleigh stability limit” where the
surface tension force no long can sustain the repulsion force. At this point, the droplets undergo
the “Coulomb fission” [109] and form smaller charged progeny droplets. The fission process will
occur repeatedly and eventually the gas-phase positive-charged peptide ions are formed.
Produced ions will pass through the heated capillary, which can help further evaporate the
remaining solvent and lead ions into the analyzer of the mass spectrometer.
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Figure 2.3. Schematic representation of the electrospray ionization process.
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One drawback of ESI in comparison with MALDI is lower sensitivity, but this has been
greatly improved by the introduction of nanoelectrospary ionization (nESI) [110]. nESI is
operated in a more narrow spray capillary at a lower flow rate of nL/min and positioned closer to
the entrance of the mass analyzer. Lower flow rate extends the analysis time and thus greatly
reduces the amount of sample needed. Also, when the flow rate is dramatically reduced, smaller
droplets are formed, leading to increased ionization efficiency, greater sensitivity and better
tolerance to salts and other impurities as compared to conventional ESI [111]. Despite these
advantages, ESI and MALDI both suffer from ion suppression due to the competition for charge
in the ionization process. For example, larger molecular, more hydrophobic ions are more easily
to be ionized and thus will be over-represented in the mass spectra [112]. To alleviate this
problem, one solution can be coupling chromatographic separations with the mass spectrometer.
For example, nESI can directly interface with 2D-LC described above (2D-LC-nESI), which
further enhances the sensitivity. Currently, nESI has become the most commonly used ionization
technique in peptide and protein analysis with limited amount of material available. For all
measurements in this dissertation, nESI coupling 2D-LC was used as the ionization method.
2.4.2 Mass analyzer and detector
After ions have been transferred into the gas phase and introduced into the mass
spectrometer, the mass analyzer is responsible for separating ions by their m/z. There are many
types of mass analyzers but not a specific one can be universal for all applications. When
choosing the appropriate instrument, one should consider the type of information required for the
biological problems and evaluate the instrument based on the following figures of merit: mass
resolution, which determines the ability to differentiate two close mass spectral peaks and
typically is given as FWHM (full width of at half maximum) of a peak; mass accuracy, which
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compares the difference between the measured mass and calculated mass and is calculated as
error corresponding to percentage or parts per million (ppm); mass range, which gives the range
of largest m/z and smallest m/z that a mass analyzer can measure; dynamic range, which
measures the ratio of datectable signal between the most abundant component and the least
abundant component; sensitivity, which is the ability to measure small differences in
concentration of an analyte and usually defined as the slope of the analytical calibration curve
(plot of signal response as a function of concentration); and scan speed, which refers to the
number of spectra can be recorded per unit time. For example, peptide sequencing are usually
achieved in ion trap analyzers that provide high sensitivity and fast scan speed, but have less
resolving power, while the characterization of intact proteins requires instruments with high
resolution and mass accuracy, in order to determine the charge state and accurate mass of the
protein. It is also noted that different types of mass analyzers can be combined together, to obtain
desirable features of all linked mass analyzers, for example liner ion trap - Orbitrap hybrid mass
spectrometer (discussed below) that delivers high resolution, speed, sensitivity and flexibility.
Despite various types of mass analyzers, ion trap mass analyzers such as linear trapping
quadrupole (LTQ) [113] and Orbitrap [114] are most commonly used in proteomic
measurements. LTQ is one type of two-dimensional linear ion trap (LIT) consisting of a square
array of four hyperbolic metal rods with a longitudinal space between them (Figure 2.4 a). A
combination of direct current (DC) and alternating current (AC) radio frequency (RF) voltage
can be applied to the metal rods to control the ion motion. Ions are trapped radially in RF electric
field and axially in a static electric field using DC voltage. Three different DC voltages are
applied to the front, center, and back section of the trap aiming to trap ions axially in the central
section of the trap. In addition, RF voltages with constant frequency but variable amplitude are
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(a)

(b)

Figure 2.4 Schematic of the Orbitrap Elite Hybrid Mass spectrometer. (a) Image source: Thermo
Scientific LTQ Series Hardware Manual, http://www.thermoscientific.com/en/product/ltq-xllinear-ion-trap-mass-spectrometer.html (b) Image Source: Thermo Scientific LTQ Orbitrap
Series Hardware Manual, http://www.thermoscientific.com/en/product/orbitrap-elite-hybrid-iontrap-orbitrap-mass-spectrometer.html
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applied to the rods and voltages are ramped during scan. When RF voltage is low, ions with a
broad range of m/z values can be trapped and stabilized in the radial direction. However, as the
RF voltage increases, ions of increasing m/z are sequentially unstable and ejected out of the rods
and into the detector system where a mass spectrum can be acquired.
Once ions are separated in LTQ, they reach the ion detector. The most commonly used
detector for LTQ is the electron multiplier [115], where ions strike the dynode and generate
electric current that can be measured. Ions striking the first dynode surface result in an emission
of electrons. These electrons then strike the second surface and more secondary electrons are
generated. As this process repeats in a series of dynodes, the electrons are multiplied and thus
initial signal is amplified by 106 or higher.
Recently, the dual cell differential pressure LIT [116] was developed to improve ion
trapping and the mass resolution. Usually, a single ion trap uses a compromised pressure
between the ion trapping/fragmentation efficiencies (can be increased in higher pressure) and
mass resolution/scan speed (can be increased in lower pressure). Therefore, in order to achieve
improvements in all events, rather than a single ion trap, the dual pressure cell uses a first high
pressure trap to trap, isolate and fragment ions, and also a second low pressure trap to scan ions
out for detection. All these improved features in sensitivity, dynamic range and acquisition speed
greatly benefit the proteomic analysis of complex samples [117].
Another type mass analyzer is the Orbitrap, which consists of a spindle-shape central
electrode and a barrel-shaped outer electrode (Figure 2.4 b) [118]. Without RF field as in LIT
analyzers, ions are trapped in a static electric field supplied by a DC voltage on the two
electrodes. The stability of ions involves a balance between an electric force (due to ions orbiting
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around the central electrode) and a centrifugal force (due to the initial velocity of ions). At the
same time, ions also oscillate along the z-axis and m/z values of the ions can be determined by
the oscillation frequencies. The ion detection in Orbitrap is an image current from the oscillating
ions and a mass spectrum is obtained by Fourier transform of this current. Such measurements in
the Orbitrap can achieve very high resolving power (up to 100k) and thus high mass accuracy
(<1 ppm). In addition, a new high-field Orbitrap analyzer was developed with a decreasing gap
between the inner and outer electrodes. This compact, high field Orbitrap analyzer provides
higher frequencies of ion oscillations and hence higher resolving power (up to 240k).
Because of the enormous sample complexity in human infant fecal samples, ultrahigh
resolution LTQ-Orbitrap Elite hybrid mass spectrometer (Thermo Scientific, Waltham, MA) was
used for peptide sequencing in this dissertation [55]. LTQ-Orbitrap Elite is a combination of two
mass analyzers, a LTQ and an Orbitrap mass analyzer (Figure 2.4 c). It features a novel ion
transmission pipeline (enhancing transfer efficiency), dual-pressure ion traps (mentioned above),
discrete dynode LTQ electron multipliers (yielding six orders of magnitude dynamic range) and
a high field Orbitrap mass analyzer (mentioned above). The system enables ultra-high resolution
(greater than 240,000 at m/z 400), high mass accuracy (<1 ppm using internal calibration), great
dynamic range (>5000), attomole-femtomole sensitivity and fast scanning speed (up to 12.5
MS/MS spectra in the rapid scan mode). All these features together enable increased proteome
coverage and a greater depth of measurement in complex samples even with very low sample
amounts.
In general, ions from the capillary pass a number of lens and multipoles (called ion optics)
and reach the ion trap. Ions are stored, isolated, fragmented and scanned by m/z in the LTQ and
ejected into the C-trap (nitrogen-filled RF-only curved ion trap). Ions trapped in the C-trap are
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then ejected into the Orbitrap for high resolution and accurate mass determination. This
particular hybrid instrument not only retains the high sensitivity and fast scanning speed from the
LTQ, but also gains high resolution and mass accuracy from the Orbitrap. This has driven the
“high-low” approach, one of the most favorite data acquisition modes in proteomics, where
precursor ions and fragment ions are measured in high-resolution Orbitrap and low-resolution
LTQ respectively [55]. All the studies in this dissertation employed the high-low approach on the
LTQ-Orbitrap Elite.
2.4.3 Data acquisition in mass spectrometry
In a full MS1 spectrum, thousands of ions with different m/z and varying intensities can
be scanned and measured. In order to obtain the peptide sequence information, precursor ions in
MS1 are selected and subjected to further fragmentation. However, even with high performance
instrument, not all precursor ions can be analyzed if one is handled at a time. Therefore, it is
critical to operate the instrument in a mode that maximizes the sequencing efficiency of the mass
analyzer. So far, two acquisition methods have been described: data-dependent approach (DDA)
[119] and data-independent approach (DIA) [120]. Two methods differ on whether the events of
peptide fragmentation depend on the precursor intensity information from MS1.
In a DDA scheme, top N (usually top 20) most abundant peptide ions are isolated and
fragmented following a MS full scan. On the other hand, in a DIA approach, the entire m/z range
is divided into a series of consecutive windows and all peaks in a given window are fragmented
simultaneously. Since the DIA sequences the peptides independent of their intensity and covers
the entire m/z range, complete sequencing of every available ion can be achieved. But cofragmentations of all peptides in a range of m/z, especially in complex samples, create a
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significant bioinformatics challenge in the data interpretation [121]. Therefore, despite the
promising advantages of DIA, DDA is still the most widely used scheme in the metaproteomics
of complex communities. Since one major drawback of the DDA is that abundant peptides can
be repetitively fragmented and thus limits the measurement depth, dynamic exclusion is
necessary to be applied [122]. It works by putting a precursor that has been already fragmented,
onto a dynamic exclusion list for a defined duration time (30s – 60s), and so that in the next full
scan, lower abundance peptides ions can be visible and have the chance to be triggered for
fragmentation. In this dissertation, all mass spectrometric measurements were performed in the
DDA mode with specific criteria discussed in each chapter.
2.4.4 Tandem mass spectrometry
As mentioned above, top abundant peptide ions are selected for peptide sequencing, which is
obtained by the tandem mass spectrometry (MS/MS) [123]. Precursor ions are subjected to
fragmentation and the m/z ratios of resulting fragment ions are measured. By reconstructing the
fragment ions, peptide sequence information can be achieved. The most common type of ion
fragmentation is the collisional induced dissociation (CID) [124] by which parent ions are
accelerated by applying appropriate voltages and collided with a neutral inert gas such as helium,
argon or nitrogen. In the collision, the kinetic energy of parent ions is converted into the internal
vibrational energy which causes the fragmentation. The mechanism of protonated peptide
fragmentation can be explained by the mobile proton model [125, 126]. When peptides are
protonated by the electrospray ionization, protons can reside in multiple sites, normally Nterminal and side chains of basic amino acids such as lysine, arginine and histidine. Once the
collision occurs, the translational energy allows protons to mobilize onto any one of the peptide
amide bonds. This weakens the stability of amide bond, thus resulting in the cleavage of the
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peptide bond. Mostly, b and y type ions are observed and a type ions can be generated by the
sub-fragmentation of b type ions (Figure 2.5) [127]. In addition, this cleavage can occur at
various amid bonds in a peptide backbone, thus generating a series of b and y type ions in a
tandem mass spectrum. Theoretically, a peptide sequence can be manually interpreted using
MS/MS spectra if b and y type ions can cover the complete peptide. However, part of fragment
ions are often missing and massive amount of MS/MS spectra can be collected in a MS
measurement, making the manual interpretation obviously impractical. Thus, computational
algorithms and tools that allow for reliable and efficient identifications of peptides, have been
successfully developed and are discussed below.

2.5 Bioinformatics
2.5.1 Database searching algorithm
The analysis of fragment ion spectra to decode peptide sequences has been significantly
facilitated by the development of various database searching algorithms. In general, these
algorithms are employed to match the collected experimental fragment ion spectra against
theoretical fragment ion spectra that have been predicted for peptide sequences from the genome
information (Figure 2.6). The vast array of experimental mass spectra is matched against a
predicted protein sequence database with an appropriate search algorithm. This process begins
by first identifying a list of candidate peptides which appear to match to the experimental spectra.
Then each potential match is scored based on the level of similarity between the experimental
and predicted fragmentation spectra. The algorithm selects the candidate with the highest score
as the identified peptide. The identified peptides are then filtered to control the false discovery
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Figure 2.5. Peptide fragmentation ion type. A peptide backbone consisting of four amino acid
residues (R1, R2, R3 and R4) and types of peptide fragmentation ions (a, b, c, x, y and z)
generated by CID. Ion types a, b and c are generated when the charge is retained on the Nterminus while ion types x, y and c are generated when the charge is retained on the C- terminus.
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Figure 2.6. Computational metaproteomics workflow. Experimental spectra are compared with a
list of candidate peptides generated from metagenome predicted database. Peptide-spectrum
matches are determined based on correlation scores with a controlled false discovery rate (FDR).
Peptides are assigned to protein groups in order to alleviate ambiguous protein identifications.
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rate (FDR) [128]. FDR is computed by searching all MS/MS spectra against the target reference
databased and also the reversed, shuffled or randomized decoy database [129]. It is calculated by
doubling the number of reverse hits over the total number of hits (forward and reverse), since
spurious random hits can occur in either forward or reverse searches. Those peptides that pass
the scoring threshold are computationally linked to appropriate proteins using an inference
approach. Due to sequence redundancies in the predicted protein sequence database, peptides
often cannot be uniquely linked to specific proteins, so they are clustered into protein groups
based on either parsimony [130] or sequence homology rules [40].
The most commonly employed database searching algorithms are SEQUEST [45],
Mascot [131], MyriMatch [132], OMSSA [133], and X!Tandem [134]. In this dissertation, all
raw files were searched with the MyriMatch algorithm. Since hundreds of thousands of fragment
ion spectra can easily be acquired per day from a typical MS metagenome databases becomes
computationally intensive. MyriMatch is a multi-threaded software that allows parallel
computing on clusters, permitting a much faster data processing and database searching. One
distinctive feature of MyriMatch is that not only the pattern of a fragment spectrum but also the
intensity of each peak is considered during the scoring of matching the observed spectrum to the
peptide sequence. Before the matching, data are pre-processed to remove noise and retain ions
based on the intensity. Rather than removing a percentage of low intensity ions, MyriMatch
retains ions by targeting a percentage (98% by default) of total ion current (TIC) for each
spectrum. Retained ions are then matched with candidate peptides using the m/z tolerance
(usually 1.5 m/z for average parent mass and 10 ppm for monoisotopic precursor mass). For each
paring of observed spectrum and candidate sequence, MyriMatch employs the multivariate
hypergeometric (MVH) distribution to compute the probability of random match and score the
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matches. In this model, matching a high intensity peak contribute more to the score. Also, an
mzFidelity score is employed to evaluate the proximity of observed and expected fragment m/z
values. With MVH and mzFidelity sores, candidate peptides are ranked and best match is
assigned.
2.5.2 Protein inference
After the database searching and peptide identifications are performed by MyriMatch,
IDPicker [135] was used to assemble the proteins. In general, IDPicker extracts sequence, scan,
intensity and score information of each spectrum from MyriMatch output files and determines
the score threshold for confident peptide identifications according to a user defined PSM FDR
cutoff. Peptides are assembled into proteins with additional peptide and protein level filters, such
as minimum spectra per peptide, minimum spectra per match, maximum protein groups,
maximum distinct peptides, minimum additional peptides and minimal spectra per protein.
IDPicker reports a list of all identified proteins/protein groups, their corresponding detected
peptides as well as spectra information including scores, mass and sequences.
To confidently identify a protein, usually one unique peptide (exclusively belonging to
one proteins) and one additional peptide are required, known as “two-peptide rule” [136].
However, unlike proteins in a single microbial isolate where most peptides can be uniquely
mapped to a single protein, a large amount of peptides can be shared among proteins from
closely related species in metaproteomics. As a result, proteins share the same set of peptides
cannot be differentiated and therefore “two-peptide rule” is difficult to be broadly applied in the
metaproteomics investigations.
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There are essentially two approaches to group proteins with shared peptides. The first
approach uses a parsimony rule with Occam’s razor constraints to identify a minimum set of
proteins to explain the identified peptides [130]. While this approach has been widely used in
proteomics and is able to minimize over-reporting the number of protein identifications, there is
no definitive evidence to determine the presence of any particular protein within a group, and
proteins in the same group may not necessarily have a similar biological function, which
precludes functional analyses. An alternative approach for protein grouping is based on sequence
homology [40]. Proteins with certain level of sequence similarity (e.g., 95%) are clustered
together. In brief, proteins in the database are sorted by descending length and the longest protein
is considered as the first “seed” protein. A pairwise comparison is performed between each
protein sequence with the seed. If a protein shares a defined degree of sequence similarity with
the seed, the protein is considered as a “hit” and joins the protein group. After the first group is
formed, the longest protein within the rest of the proteins becomes the new seed protein and
compares with subsequent proteins. By such, peptides that are not previously unique to
individual proteins now can be unique to a protein group. Due to such high sequence similarity,
all proteins clustered within the same group are likely to have similar biological functions. This
grouping scheme allows functional analysis and relative quantification of metaproteomics at the
protein group level, which helps simplify the data interpretation. Further details are discussed in
Chapter 4.
2.5.3 Protein quantification
In a label-free mass spectrometric measurement, proteins are typically quantified using
spectral count, which is the number of tandem mass spectra matching peptides to a particular
protein [137]. The more abundant proteins and peptides are, the more times they can be observed.
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Therefore, spectral count can be used to compare proteins in the relative abundance between
samples. For this dissertation, proteins are quantified with spectral counts and normalized by
total number of spectra collected in each measurement.
Instead of using the discrete counts, recent studies have suggested a protein quantification
method based on the signal intensity, termed matched ion intensity (MIT) [138]. For every PSM,
the intensity is calculated by summing up the intensities of all fragment ions matched to that
peptide. One obvious advantage of MIT is that larger analytical dynamic range can be achieved
as compared to the limited number of spectral counts acquired in a MS experiment. Comparisons
of two methods in the quantification of gut metaproteomics are discussed in Chapter 4.
Typically, a protein’s spectral count or MIT is the sum of all its peptides’ spectral counts
or intensities. However, a number of peptides can be shared by multiple proteins/protein groups
in a proteomic study. There are several ways we could have assigned these shared spectral counts
or intensities, basically three strategies: 1) discarding shared spectral count or MIT and only
considering unique peptides for protein abundance; 2) adding the full spectral counts or MIT of
shared peptides to each of shared proteins/protein groups; or 3) distributing a portion of spectral
counts or MIT to the shared proteins/protein groups, which is termed as the spectral balancing. In
general, spectral balancing distributes shared spectral counts or MIT according to the number of
unique peptides in each protein/protein group. Proteins/protein groups with greater proportion of
unique peptides will be assigned with a greater share of the shared peptide’s spectral counts or
intensities. For this dissertation, the balancing strategy has been used for assigning shared
spectral counts.
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2.5.4 Functional groups assignment
Once thousands of proteins are identified, several approaches /databases can be used to
assign proteins into functional groups. These groups summarize/group functionally similar or
related proteins and aid in our understanding of functionalities in a broader scale than looking at
individual proteins. These databases include the Cluster of Orthologous Genes (COG) [73], the
Kyoto Encyclopedia and Genes and Genomes (KEGG) Orthology (KO) [139] and the Gene
Ontology (GO) [140]. Among these three databases, COG database contains less levels of
functional groups and usually provides broad categories that cannot capture enough details in the
functional characterization. KO and GO are more branched and KO can be used to map proteins
onto KEGG pathways while GO provides descriptions of proteins in terms of their associated
biological processes (BP), cellular components (CC) and molecular functions (MF) independent
of organism information. For this dissertation, all three databases have been employed for
understanding high-level functions of gut metaproteome.
Overall, the methodologies presented in this chapter demonstrated the ability to conduct
metaproteomics measurements and functional characterization in the infant gut microbiome.
Further, in the next two chapters, we will discuss the evaluation and optimization of the pipeline
and provide both experimental and informatics strategies with careful considerations, in order to
address the unique challenges posed by infant gut metaproteomes.
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CHAPTER 3
Development of an enhanced metaproteomic approach for deepening the
microbiome characterization in the human infant gut
Text and data presented below were adapted from:
Weili Xiong, Richard J. Giannone, Michael Morowitz, Jillian F. Banfield, Robert L. Hettich.
Development of an Enhanced Metaproteomic Approach for Deepening the Microbiome
Characterization of the Human Infant Gut. J Proteome Res 2015, 14 (1), pp 133–141.
Weili Xiong’s contributions included: experimental design, sample preparation of fecal samples,
mass spectrometry experiments, data analysis, wrote, edited and revised the manuscript.

3.1 Introduction
Trillions of microbes, representing more than one thousand bacterial species-level
phylotypes, colonize the adult human intestinal tract [63], generating a complex ecosystem that
influences many aspects of human health and diseases [3, 70, 71, 141]. In particular, the gut
microbiota plays a crucial role in protecting against pathogen invasion, processing nutrients,
balancing energy, and regulating host immune responses [64, 142-144]. Microbial colonization
in the gut is initiated immediately after birth and undergoes remarkable changes in composition
and function over the first 2-3 years of life until a resilient, stable, adult-like microbiota is
established [88, 145]. This early-life microbiota development requires an intricate balance
between microbial colonization and the corresponding responses of human host intestinal
environment [146]. Distortions in the establishment of normal gut microbiota and commensal
microbes increase the risk of inflammatory diseases, such as necrotizing enterocolitis (NEC), via
disruption of the mucosal barrier and subsequent impairment of immune system [93, 147].
Despite a lower complexity than adult microbiota, the gut microbial communities in infants are
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highly variable between individuals and may be influenced by a number of external factors, such
as delivery mode, diet, and antibiotic use [148-150].
Two recent studies based on metagenomic data from fecal samples from two healthy
premature infants have detailed both the microbial species/strains present as well as their relative
abundances during the first month of life [21, 151]. Both genomic analyses revealed shifts in
bacterial populations, identifying discreet compositional phases during infant gut colonization.
Interestingly, the gut microbiota structure was drastically different between the two infants.
Specifically, Citrobacter, Serratia and Enterococcus species were dominant microbial members
in one infant, while Enterococcus faecalis, Propionibacterium carrol and four different
Staphylococcus epidermidies strains were dominant in the second infant. Although metagenomic
information alone highlights community variation and provides a list of all possible gene
proteins, metaproteomics provides insight into real-time functional signatures which help detail
metabolic activity as well as host/microbe interaction during gut colonization.
Shotgun metaproteomics via nanospay two-dimensional liquid chromatography coupled
with tandem mass spectrometry (nano 2D LC-MS/MS) provides a powerful platform for the
large-scale characterization of metaproteomes [152]. Notwithstanding, the interrogation of the
infant gut proteome is impeded by several major factors: (1) large diversity in gut microbial
composition between individuals; (2) wide dynamic range of protein abundances; (3) insufficient
genome information/assembly. The advancement of high performance mass spectrometry has
greatly increased proteome coverage, including quantification [27], in complex samples and the
use of matched metagenomes enables more confident and accurate protein identification;
coupled together, remarkable success has been demonstrated for a number of diverse and
complex fecal samples [10, 27, 72].
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Our initial investigations to test metaproteomics for the characterization of premature
infant gut microbiomes simultaneously monitored both microbial and human proteins over the
first few weeks after birth. Intriguingly, the data showed dramatic variations in human to
microbial protein ratios among various infants [99]. In some cases, overwhelmingly abundant
human host proteins greatly overshadowed the microbial microbiome, resulting in reduced depth
of measurement into the microbial proteome. These highly abundant human proteins precluded
the efficient mass spectrometric detection of medium- to low-abundance microbial peptides. In
particular, microbial peptides co-eluting near dominant human peptides experience ion
suppression and are thus more difficult to measure. Furthermore, the reduced detection and
subsequent identification of those peptides not only lowers the number of protein identified, but
also the number of unique peptides. The lack of unique microbial peptides detected makes
protein inference difficult, especially when considering closely related strains/species. These two
issues thereby inhibit the complete characterization of diverse gut microbial communities and
must be addressed. Although microbial cell enrichment in fecal samples by differential
centrifugation has been previously reported [10, 72], infant fecal samples are limited by the
amount of raw material available, thus precluding the differential centrifugation approach and
necessitating the development of alternative enrichment strategies.
The objective of this work was to develop and demonstrate the feasibility of an enhanced
metaproteomic sample preparation strategy that provides more comprehensive interrogation into
the infant gut microbiome by incorporating a double filtering (DF) separation step that
selectively depletes human cells and proteins while enriching microbial biomass in the fecal
sample. With the inclusion of this DF, we observed a significant increase in the number of
microbial protein identifications at the calculated expense of human proteins which affords a
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more extensive characterization of microbial functionality in the infant gut without too much
interference from high abundance human proteins.

3.2 Materials and methods
Sample Collection. Fecal samples from two premature infants (#UN1 and #CA1) were supplied
by Dr. Michael Morowitz and stored at -80 ̊C. Samples were obtained under an IRB agreement
protocol, and were de-identified before sending to ORNL. A small portion of sample was excised
and thawed prior to cell lysis and protein extraction.
Protein Extraction and Enzymatic Digestion. For each infant, approximately 0.5 g of raw fecal
material was processed by two methods: a direct method and an indirect double filtering (DF)
method. For the direct method, fecal material was boiled for 5 min in 1ml lysis buffer containing
100 mM Tris-HCl, pH 8.0, 4% w/v SDS (sodium dodecyl sulfate) and 10 mM dithiothreitol
(DTT). The suspension was vortexed and sonicated with a Branson ultrasonic cell disruptor (20%
amplitude for 2 min, 10 s pulse with 10 s rest). Crude protein extract was pre-cleared via
centrifugation at 21,000g for 10 min, and quantified by the BCA assay (Pierce Biotechnology,
Waltham, MA). An aliquot pertaining to ~1 mg of protein was collected and precipitated by 20%
trichloroacetic acid (TCA) at -80 ̊C overnight. Protein pellets were washed with ice-cold acetone,
resuspended in 8 M urea, 100 mM Tris-HCl, pH 8.0 and sonically disrupted in order to fully
solubilize the protein pellet (20% amplitude for 5 min, 10 s pulse with 10 s rest). Denatured
proteins were reduced with 5 mM DTT for 30 minutes. To block disulfide bond reformation, 20
mM iodoacetamide (IAA) was added to each sample; the reaction occuring in the dark at room
temperature for 15 minutes. Samples were diluted to 4 M urea in 100 mM Tris-HCl, pH 8.0 and
digested with one aliquot of sequencing grade trypsin (Promega, Madison, WI; 1:100 (w/w))
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overnight at room temperature. Following digestion, samples were diluted to 2 M urea for a
second digestion that lasted 4 hrs. Digested samples were then adjusted to 200 mM NaCl, 0.1%
formic acid (FA) and filtered through a 10 kDa cutoff spin column filter (Vivaspin 2, GE Health,
Pittsburgh, PA) to remove under-digested proteins. Peptides were quantified by the BCA assay
and stored at -80 ̊C until use. For the indirect DF method, a differential filtering method was
designed and optimized based on the knowledge that bacterial cells (0.2-2 µm in diameter) are
typically much smaller than human cells (10-100 µm in diameter). In addition, bacterial cells
usually contain chemically complex cell walls and therefore are more resistant to mechanical
shear force, while human cells are much more susceptible and easier to lyse. Prior to the
detergent-based cellular lysis and protein extraction described above, two different-size vacuum
filter units were employed to physically separate human from microbial cells (Figure 3.1). Fecal
samples (0.5 g) were suspended in 10 mL ice-cold Tris-based saline (TBS) buffer and passed
first through a 20 µm vacuum filter unit to remove larger fibrous material and intact human cells.
The filtrate (including microbial cells, small human cells, secreted human and microbial proteins
and proteins from lysed cells) was homogenized using VDI 12 homogenizer (VWR, USA) at
speed 6 (30,000 rpm, 30 s-resting 30 s-30 s) to disrupt remaining intact human cells, followed by
centrifugation (4000 x g, 10 min) to pellet intact bacterial cells. The collected pellet was
resuspended in 10 ml cold TBS and passed through a second 0.22µm vacuum filter unit. This
permitted human proteins to be washed through while microbial cells were captured on the filter.
Captured cells were washed twice with cold TBS to remove attached human proteins and lysed
by the SDS-based approach as described above. The entire filtering process was performed on
ice and completed within 20 min to minimize proteomic perturbations during manipulation.
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Figure 3.1. Workflow of the indirect double filtering (DF) method. Fecal raw material is
suspended in cold PBS and passed through a 20µm filter to remove large particles and intact
human cells. The filtrate is homogenized and centrifuged to obtain a microbial cell pellet. The
pellet is resuspended and passed through a 0.22µm filter to collect microbial cells on the filter
membrane. Collected cells are washed twice and subjected to SDS based cell lysis and protein
purification method.
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Nano 2D LC-MS/MS Measurement. Proteolytic peptide samples were analyzed via an online
nano 2D LC-MS/MS system interfaced with a hybrid LTQ-Orbitrap-Elite MS (ThermoFisher
Scientific). A 30 µg aliquot of peptides was loaded onto a biphasic silica back-column and
analyzed by a three-step MudPIT as described in Chapter 2. The LTQ-Orbitrap-Elite was
operated in a data-dependent mode with each full scan (1 microscan) collected in the Orbitrap
mass analyzer at 30,000 resolution, followed by collision-induced dissociation (35% energy) of
the top 20 most abundant parent ions (1 microscan). Dynamic exclusion was enabled with a mass
exclusion width of 0.2 m/z and exclusion duration of 60 s.
Protein Database Construction and Searching. Due to the lack of a sample-specific
metagenome-derived protein database for infant #UN1, a pseudo-metagenome was created by
concatenating 21 microbial isolate reference genomes (acquired from JGI; representative
organisms were chosen based on 16S rRNA information from another infant sample that was
quite similar to this particular infant (Table 3.1)), human protein sequences (NCBI RefSeq_2011)
and common contaminants (eg. keratin and trypsin) into a single protein database (105,671
sequences). Though not metagenomically matched, this database provides complete genome
sequences of presumably present microbial species, as indicated by 16S rRNA analysis.
Conversely, a matched metagenome-derived protein database (60,073 sequences) for infant
#CA1 was generated by combining metagenomic sequences [21] collected on postnatal days 10,
16, 18 and 21 from the infant (provided by Dr. Jillian Banfield), along with human protein
sequences and common contaminants. A decoy database consisting of reverse protein sequences
was appended to the target database to calculate false discovery rates (FDR). All MS/MS spectra
were searched with the Myrimatch v2.1 algorithm [132] against the appropriate database with the
following configuration parameters: fully tryptic peptides with any number of miscleavages, an
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Table 3.1. 21 microbial isolate reference genome database
Genome
Acinetobacter junii SH205

Eubacterium rectale ATCC 33656

Bifidobacterium adolescentis ATCC 15703

Fusobacterium sp. 1_1_41FAA

Bacteroides fragilis NCTC 9343

Klebsiella sp. 1_1_55

Bifidobacterium longum infantis ATCC

Leuconostoc mesenteroides cremoris ATCC

15697

19254

Campylobacter concisus 13826

Lactobacillus reuteri 100-23

Citrobacter koseri ATCC BAA-895

Pseudomonas aeruginosa PAO1

Citrobacter sp. 30_2

Staphylococcus aureus 04-02981

Clostridium sporogenes ATCC 15579

Serratia odorifera 4Rx13

Enterobacter cancerogenus ATCC 35316

Streptococcus sp. 2_1_36FAA

Escherichia coli K12 DH10B

Weissella paramesenteroides ATCC 33313.

Enterococcus faecalis TX0104
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average precursor mass tolerance of 1.5 m/z, a mono precursor mass tolerance of 10 ppm, a
fragment configuration parameters: fully tryptic peptides with any number of miscleavages, an
average precursor mass tolerance of 1.5 m/z, a mono precursor mass tolerance of 10 ppm, a
fragment mass tolerance of 0.5 m/z, a static cysteine modification (+57.02 Da), an N-terminal
dynamic carbamylation modification (+43.00 Da) and a dynamic oxidation modification
(+15.99). Peptides identifications were filtered with IDPicker v 3.0 [135] to < 1% peptide FDR
(at the peptide level: maximum Q value < 2%, minimum one spectra per peptide and minimum
one spectra per match; at the protein level: minimum two distinct peptides, minimum zero
additional peptide and minimum two spectra per protein).
Protein Inference and Semi-quantification. Due to the high degree of sequence homology and
redundancy in the human RefSeq database, as well as homologous proteins from different
microbial species, peptides that map to multiple proteins increase the ambiguity within protein
identifications and quantification. To avoid under- and over-counting protein identifications, the
pseudo predicted protein database for infant #UN1 was clustered based on 90% amino acid
sequence similarity using USEARCH v 5.0 software [153], as described previously [40]. This
was done post-database search and is essentially a reassessment of uniqueness based on the very
conservative sequence identity of 90-100%. Considering the lower level of homologous protein
overlap within the constructed matched metagenome for infant #CA1, microbial proteins in the
database were clustered into a group if they share 100% amino acid sequence identity (which
would otherwise prevent proteomic identification based on the commonly used unique peptide
criterion), and human proteins were clustered based on 90% amino acid sequence similarity.
Spectral counts were balanced between shared proteins, and normalized by total numbers of
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collected MS/MS of this run as previously described [40]. Data were plotted with OriginPro 8.1
graphing software (OriginLab Corporation, Northampton, MA).
Clusters of Orthologous Groups (COGs) Assignment. Protein sequences were searched
against the COG database from NCBI using rpsblast [154] and the top hit was assigned with an
e-value threshold of 0.00001. Assigned COGs were grouped into COG functional categories to
predict functions in the gut microbiome. Abundance of each category was determined by
summing normalized spectral counts of all COGs in the category.

3.3 An enhanced strategy for infant fecal proteomics to improve the overall depth of
proteome measurement
To determine the feasibility and robustness of our enhanced approach for diverse samples,
we selected fecal samples from two healthy premature infants (#UN1 and #CA1) that differed by
human protein composition (as evident from the direct measurement method) and matched
metagenome availability (See database construction in Methods and Materials for details in this
study). To assess the sample preparation reproducibility and range of this method, we initially
conducted replicate sample preparation processing (complete protocol) and MS measurements on
an independent third preterm infant fecal sample. The overall correlation was high (R2 = 0.85;
Figure 3.2), verifying that the sample preparation approach was robust and reproducible.
Technical replicates were performed for each fecal sample and were found to be highly
reproducible (R2 > 0.95) (Figure 3.3), which attests to the precision of the MS measurements as
well as the enhanced search approach relative to previous methods [155].
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Figure 3.2. Reproducibility of methodological (sample preparation) replicates. An infant fecal
sample was processed twice and measured in duplicate across two 24 h MudPIT runs. A
scatterplot was generated using log2 spectral counts of protein groups in duplicate runs (R2 =
0.85). Dashed line indicates a perfect 1:1 correlation.
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Figure 3.3. Protein group quantification reproducibility. Scatter plots are constructed using log2
spectral counts of protein groups measured in duplicate runs of infant #UN1 by the direct (a, R2
= 0.95) and the indirect method (b, R2 = 0.95), and of infant #CA1 by the direct (c, R2 = 0.98)
and the indirect DF method (d, R2 = 0.94). Dash line indicates the perfect correlation.
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The results of protein group identifications and spectra assignments for premature infants
#UN1 and #CA1 are summarized in Tables 3.2. The task of mapping peptides to proteins for
metaproteomic investigation is challenging in that peptides can be shared by multiple proteins in
a reference database, which result from homologous proteins among closely related organisms
and/or sequence redundancies within large databases. These shared peptides are common in
infant gut databases and lead to ambiguous protein assembly, especially relative to more routine
microbial isolate measurements. Previous studies proposed an effective way to deal with shared
peptides by clustering proteins into groups using an algorithm based on sequence homology [40].
This protein grouping approach affords distinct advantages in data interpretation, since proteins
sharing high similarity are likely to exhibit similar biological functions, allowing for a more
robust interrogation of functional activities in complex communities such as the infant gut. Based
on this approach, a total of 807 or 1264 (for infant #UN1) and 342 or 1012 (for infant #CA1)
protein groups (non-redundant protein groups from duplicates) were generated using the direct
and the indirect DF method, respectively (FDR rate < 1% at the peptide level, Table 3.2).
Having established the criteria for protein identifications, we sought to assess the overall
depth of proteome coverage by this enhanced strategy. Indeed, our approach facilitated a
noticeable increase in the number of overall spectra assignments and greater than 50% peptide
and protein group identifications for both infant fecal microbiomes compared with the
measurement using the direct approach (Table 3.2). Notably, greater improvements were
observed for infant #CA1 relative to infant #UN1. This may be due to a more representative
database constructed from matched metagenome of infant #CA1, providing a more complete
protein inventory and thus more confident protein identifications, but more likely, the increase
resulted from greater removal of human proteins, since #CA1 contained a higher abundance of
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Table 3.2. Overview of proteomic results from two fecal microbiomes measured by the direct
and the indirect DF method

Infant #UN1
Direct

Direct

Run

Spectral
counts
Peptide
counts
Protein
counts

Infant #CA1

Indirect Indirect
DF

DF

Direct

Direct

Indirect Indirect
DF

DF

Run1

Run2

Run1

Run2

Run1

Run2

Run1

Run2

40495

39432

42485

42544

40068

41492

45484

47221

4156

4672

6688

6799

1968

1905

4475

4238

2215

2465

3534

3697

691

542

1200

1182

655

734

1076

1122

304

289

855

854

Protein
group
counts
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human proteins (Table 3.3). Since the measurement of complex protein mixtures is often biased
towards high abundance proteins, which generate an excess of proteolytic peptides that often
occupy long periods of chromatographic space and limit the dynamic range of the measurement
by precluding sampling (and identification) of co-eluting, lower abundance microbial proteins, a
larger initial complement of human cells in #CA1 would have been affected more by the indirect
DF method.
Once abundant proteins were removed with DF, we were able to dramatically increase
identifications for those previously unmeasured microbial proteins. In fact, we observed
differences in the protein abundance profiles between the two methods for both infants, with
specific increases in the number low abundant proteins groups (less than 100 spectral counts;
Figure 3.4). As a result, we achieved a deeper proteome characterization, primarily in the
microbial membership.

3.4 Microbial protein group identifications are enriched by depletion of abundant human
proteins
The success in achieving accurate protein identifications and deep proteome coverage in
a complex community relies on the quality of predicted protein sequence database that is
constructed from metagenomic data. Compared to the analysis of a single cell type / microbial
isolate, a larger portion of high quality spectra in metaproteomic study remain unassigned due to
the incompleteness of the proteomic database. To quantify this, we employed a spectral quality
assessment tool, ScanRanker [156], to assign scores for all the collected spectra to evaluate the
quality of the database. Using ScanRanker scores, a distribution of total collected spectra
including unassigned, assigned human, and assigned microbial spectra was plotted for each
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Table 3.3. Collected and assigned mass spectra results

Infant #UN1

Infant #CA1

Run

Direct

Indirect DF

Direct

Indirect DF

Collected

286530

286671

279174

278277

Assigned

80322

86001

81937

93728

Human

47165

6221

78260

48550

Microbial

32730

78675

3277

44021
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Figure 3.4. Rank-abundance plots of protein groups. Identified proteins are clustered into protein
groups and their spectral counts are balanced and normalized according to the approach specified
in Materials and Methods. Protein groups of (a) infant #UN1 and (b) infant #CA1 are ranked and
plotted based on spectral counts. The indirect DF method facilitates an increasing number of
identified protein groups. The two methods possess the same slope for top ranked groups but
diverge at the group with fewer than 100 spectral counts. The indirect DF method has shallower
slope and thus provides more low abundance protein group identifications.
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infant, as measured by both methods (Figure 3.5). For each distribution, a total of ~280,000
spectra were represented, as measured in duplicate runs, and ~15% of those with scores below 0.6 were recognized as peptide identifications, implying lower quality spectra reside at the lower
end of collected mass spectra can be assigned to peptides for an organism with a completely
sequenced genome (without accounting from PTMs, sequence variants, and other unknown
contaminants, of course). However, due to the increased complexity of these samples, as well as
the fact that the metagenomic databases used here are incomplete, approximately 27% and 29%
of total collected spectra were assigned for infant #UN1 and infant #CA1, respectively, using the
direct approach (Figure 3.5 (a) and (b)), while a slightly higher percentage of 30% and 33% were
achieved via the indirect DF approach (Figure 3c and 3d). Despite similar spectral assignment
efficiency, one readily observable difference between the two infants is the ratio of human versus
microbial assigned spectra. For infant #UN1, the microbial peptide spectral matches (PSMs)
accounted for 40% of total assigned spectra with the direct method (Figure 3.5 (a)) while for
infant #CA1, this value was much lower (~4%). Consequently, this suppression of microbederived PSMs by the presence of abundant human proteins severely impedes the interrogation of
microbial functional activities in the gut, especially when considering semi-quantitation (Figure
3.5 (b)). Therefore, it is a challenge to investigate the inter-individual variability through the
direct approach given the relative dearth of microbial PSMs. However, compared to the direct
method, our DF strategy substantially increased microbial PSM proportions within total assigned
spectra, from 40% to 93% for infant #UN1, and from 4% to 48% for infant #CA1 (Figure 3.5).
Although it depends on the experimental question being asked, the ultimate goal here was
to remove abundant human proteins and peptides in order to enhance microbial protein
identification depth - a process that would undoubtedly facilitate functional characterization at
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Figure 3.5. Distributions of ScanRanker scores for collected mass spectra. ScanRanker scores are
used to assess spectral quality for all collected mass spectra. Stack histograms are generated for
ScanRanker scores of (a) infant #UN1 measured by the direct method, (b) infant #CA1 by the
direct method, (c) infant #UN1 by the indirect DF method and (d) infant #CA1 by the indirect
DF method. The color encodes ScanRanker score distributions of unassigned (gray), assigned
human (red) and assigned microbial (green) mass spectra in replicates. The indirect DF method
enriches microbial mass spectra assignment as decreasing human mass spectra assignment.
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the microbial-level. Using infant #UN1 as a test case, we found that 593 protein groups overlap
between the two methods, with 214 protein groups uniquely identified by the direct method and
671 protein groups uniquely identified by the indirect DF method (Figure 3.6 (a)). We next
evaluated Venn groupings at the PSM-level, specifically on the PSM partitioning between
organisms (i.e. human-derived PSMs vs. microbial-derived PSMs). In this case, spectral counts
were averaged between replicates. Considering protein groups specific to either method, more
unique human protein groups (155 out of 214) were found by the direct method, while more
unique microbial protein groups (649 out of 671) were detected in the indirect DF method. Of
those commonly identified between the two methods, DF led to the identification of substantially
more microbial PSMs. Collectively, our enhanced approach facilitated a 2-fold increase in the
number of identified microbial protein groups and a 2.4-fold increase in the microbial spectral
counts. Taken together, these observations indicate that improving the overall protein/peptide
identification rate/sampling depth of the microbial complement of a fecal sample was attributed
to the significant depletion of human proteins. Similar analyses of infant #CA1 further validated
the enrichment of microbial protein groups (Figure 3.7 (a)).
We also examined the identification reproducibility and quantification consistency of the
two methods regarding microbial protein groups. Over 90% of microbial protein groups
identified by the direct method were also identified by the indirect DF method (Figure 3.7 (b)
and (c)). There was a high rank correlation (rs = 0.76 for infant #UN1; rs = 0.77 for infant #CA1)
of log2 spectral counts between the two methods, with the correlation offset likely due to
microbial protein enrichment (Figure 3.6 (b) and (c)). These results demonstrate that increases in
microbial PSM rate through the DF method does not bias the sample, but instead provides more
confidence for microbial protein quantifications through selective enrichment.
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Figure 3.6. Comparison of protein group identification and quantification results by two methods.
The Venn diagram (a) shows unique and overlapped protein group identifications of infant #UN1
between the direct and the indirect DF method. Bar charts indicated human (red) versus
microbial (green) protein group counts and spectral counts in the part of uniquely identified by
the direct method (left), commonly identified (bottom) and uniquely identified by the indirect DF
method (right). Scatter plots are constructed using log2 spectral counts of microbial protein
groups measured by two methods for infant #UN1 (b, rs = 0.76) and infant #CA1 (c, rs = 0.77).
Solid line indicates the perfect correlation and the dash line indicates the offset owing to
microbial protein enrichment. Microbial protein groups are enriched with a relatively high
ranked correlation.
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Figure 3.7. Microbial protein group identification. The Venn diagram (a) shows unique and
overlapped protein group identifications of infant #CA1 between the direct and the indirect DF
method. Bar charts indicate human (red) versus microbial (green) protein group counts and
spectral counts in the part of uniquely identified by the direct method (left), commonly identified
(bottom) and uniquely identified by the indirect DF method (right). The Venn diagrams (b, infant
#UN1) and (c, infant #CA1) show the overlap of microbial protein group identifications of two
infants between two methods. Over 90% of microbial protein groups in the direct method are
identified by the indirect DF method.
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3.5 Enriched microbial protein identifications facilitate more comprehensive information
for microbial functional categorization
To further elucidate the advantages of the DF sample preparation approach, we tabulated
and analyzed the COG functions for the two infant gut microbiomes measured by these two
methods. We clearly recognize that COG families are relatively broad and characterize the
functionality at a lower resolution than a more specific, detailed metabolic pathway analysis.
Nevertheless, they were used here only to provide a general metric for the power of microbial
protein enriching approach and not necessarily to assess biological differences between the two
infants. For both infants, we found several highly represented COG categories, including
Carbohydrate transport and metabolism, Energy production and conversion, Translation,
ribosomal structure and biogenesis, Posttranslational modification, protein turnover,
chaperones and Amino acid transport and metabolism (Figure 3.8). A similar distribution of
COG functions was reported for a healthy adult twin pair [72]. These results suggest that the
establishment of microbial communities in these two infants gut environments is fairly quickly
migrating towards a relatively stable and adult-like microbiota, which plays a crucial role in
carbohydrate metabolism and nutrient production.
An in-depth inquiry into infant gut microbiota establishment during early life, as well as
identifying the relationship between microbiota and inflammatory disorders, requires delineation
of the full range of microbial functions, especially those that are seemingly of low abundance.
For infant #UN1, human proteins were only moderately abundant, and so the enrichment of
microbial proteins did not change the overall pattern of COG categories but allowed both more
confident protein identifications as well as an order of magnitude deeper spectra assignment for
each functional category. This enhancement provided deeper protein signatures with better
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Figure 3.8. COG category analysis of microbial protein groups. Microbial protein groups are
assigned into COG categories via rpsblast against the COG database from NCBI. Distributions of
identified categories were constructed by category counts and spectra of infant #UN1 (a) and
infant #CA1 (b). Abundant categories are numerically labeled.
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statistics and better coverage of specific cellular pathways. However, for infant #CA1, human
peptides dominated the identifications, leading to suboptimal microbial protein binning into
COG categories for the direct method. Conversely, employing the DF strategy allowed us to
significantly improve the resolution of microbial functional category determination/assignment,
resulting in newly identified categories of Cell wall/membrane/envelope biogenesis, Coenzyme
transport and metabolism, Intracellular trafficking secretion and vesicular transport, Nucleotide
transport and metabolism, Replication, recombination and repair, and Signal transduction
mechanisms. Based on the indirect DF approach, the microbiota of two infants intriguingly
shared the similar COG function profiles despite tremendous taxonomic diversity, suggesting
functional redundancy in the early intestinal ecosystem. Clearly, this approach sets the stage for
more detailed time course measurements and expanded gene ontology / metabolic mapping
analyses

that

should

provide

a

higher

resolution

delineation

of

microbiome

development/stabilization/functional activities during early infant life.

3.6 Conclusions
In this study, we report a novel metaproteomic method for extensively interrogating
infant gut microbiome. By performing a double filtering strategy on the raw samples, we
successfully enriched relatively low abundant microbial proteins from complex fecal samples
containing dominant human host proteins, while preserving the relative distribution of protein
abundances in each sample. This provided an in-depth microbial metaproteome measurement
with greater than two-fold increase in microbial protein identification and quantification with
relatively high correlated quantification, which improved our ability to confidently and
comprehensively characterize microbial functional categories for complicated gut metaproteome.
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Moreover, although the supernatant and filtrate generated by this approach were not examined in
this study, these samples could be useful for future analyses that focus on human proteome and
host responses to gut microbiome.
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CHAPTER 4
Instrumental and informatics considerations for metaproteomics
Part of the text below was adapted from:
Weili Xiong, Paul Abraham, Zhou Li, Chongle Pan, Robert L. Hettich. Microbial
metaproteomics for characterizing the range of metabolic functions and activities of human gut
microbiota. Proteomics, 2015, 15 (20), 3424-3438.
Weili Xiong’s contributions included: literature review, manuscript writing in experimental
workflow and human gut metaproteoimcs studies sections, data analysis, and manuscript editing.
Abraham, P. E., Giannone, R. J., Xiong, W., Hettich, R.L., Metaproteomics: Extracting and
Mining Proteome In-formation to Characterize Metabolic Activities in Microbial Communities.
Current Protocols Bioinformatics 2014, 13 (26), 11–14.
Weili Xiong’s contributions included: figure generation and manuscript editing.

4.1 Introduction
Mass spectrometry based proteomics have enabled identifications of thousands of
proteins in complex environmental samples, providing insights unachievable by classical
biological approaches. However, proteomics analysis, especially metaproteomics, can be
challenging as a comprehensive proteomic measurement by LC-MS/MS not only requires the
ability to deal with samples properly, but also optimal instrument settings and appropriate
bioinformatics analysis. In particular, the success of gut metaproteomics is affected by depth of
the measurement, construction of a protein database, assessment of spectra quality, unambiguous
protein inference and accurate protein quantification. In this chapter, we will discuss all above
instrumental and informatics considerations and illustrate possible strategies with the aim of
providing a reliable metaproteomic pipeline for the analysis of gut metaproteomes.
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4.2 Enabling monoisotopic precursor selection for in-depth proteome measurement
As mentioned in Chapter 3, in-depth microbial protein identifications of infant fecal
samples are inhibited by the presence of a few abundant human proteins. During MS
measurements, these abundant proteins are repeatedly sampled and prevent the detection of coeluting low abundance proteins. Although the dynamic exclusion is typically used to increase the
measurement depth, the exclusion width is particularly critical when selecting peaks onto the
exclusion list [122]. For example, an exclusion width of 1.5 m/z excludes the entire isotopic
package from sampling, which effectively avoids re-sampling the same peptide but at the same
time throws out other peptides that are co-eluted within the 1.5 m/z window. Another option that
sets the exclusion width at a tighter window (0.2 m/z) doesn’t exclude the whole isotopic
distribution. Although protein quantifications can be improved, sampling isotopic peaks of the
same peptide greatly bias the abundant peptides and limits the depth of measurement.
In the data-dependent acquisition (DDA) mode, monoisotopic precursor selection (MIPS)
can be enabled or disabled [157]. When enabling this option, only the monoisotopic peak of the
entire isotopic package will be selected for fragmentation. On the other hand, if this option is
disabled, all isotopic peaks are accessible for fragmentation. In the MIPS-enabled method, the
exclusion width can be set as tight as possible (typically 10ppm) to prevent any co-eluting
peptides from being excluded due to the wide exclusion window. In addition, only monoisotopic
peaks of peptides are subjected to MS/MS, and therefore, isotopic peaks of the same peptide
won’t be re-sampled, which avoids the repeat sampling of abundant species. A recent study has
shown that enabling this option results in significant improvement in proteome coverage and
depth [157]. Here, we evaluated how MIPS affected protein identifications in the infant gut
metaproteomics.
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One fecal sample was prepared using the direct TCA method described in Chapter 3. As a
comparison, 50µg peptides were measured via 2D-LC-nESI-MS/MS on LTQ-Orbitrap Elite in
data-dependent mode with MIPS enabled or disabled, and results were displayed in Table 4.1.
Enabling MIPS facilitated less number of total collected and assigned spectra but gained three
times of peptide and protein identifications, compared to the MIPS-disabled scheme.

The

increase of protein identifications was obtained in both human and microbial proteins, and can be
observed in not only low abundance proteins (with spectral counts below 5), but also medium
and medium high abundance proteins (with spectral counts ranging from 5-100) (Figure 4.1).
This indicated that newly identified proteins were not acquired by an increasing number of
random samplings of very low abundance species but by gaining the chance to measure co-eluted
peptides that were overshadowed by abundant peptides.
Although top 20 abundant ions in a full MS are expected for MS/MS, it is possible that
there are less than 20 available monoisotopic peaks in a full MS when enabling the option.
Indeed, it was noticed in all 11 salt-pulse steps that many full scans were followed by less than
20 MS/MS events (Figure 4.2). This was observed during the salt pulse when no or very few
peptides were transferred into the mass spectrometer as well as during the elution of very
abundant peptides when these peptides were so dominant that overall peptides were less diverse.
As a result, the instrument spent more time in MS1 scanning, which might explain why MIPSenabled measurements collected less total MS/MS.
To evaluate the depth of measurements using two different options, MS1 percentage was
calculated for every MS/MS scan in all salt-pulse steps（Figure 4.3). Basically, all peaks in a
full MS were ranked from high to low intensity. For every MS/MS scan, the rank of its precursor
ion in the full MS can be obtained according to the intensity. MS1 percentage was calculated by
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Table 4.1. Comparisons of collected/assigned spectra, identified peptides/proteins with MIPS
enabled and disabled

Monoisotopic
precursor disabled
Monoisotopic
precursor enabled

Total

Total

No. of

No. of

No. of

No. of

Collected

Assigned

identified

identified

human

microbial

Spectra

Spectra

peptides

proteins

proteins

proteins

427909

123069

3352

955

883

72

387082

91618

9494

3105

2623

482
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Figure 4.1. Number of high and low abundance identified proteins with MIPS enabled and
disabled. Identified human (red) and microbial (green) proteins were counted in four different
groups (with spectral counts larger than 100, between 10 and 100, between 5 and 10, and below
5)
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Figure 4.2. Number of MS/MS events followed by every full MS scan in 11 salt pulse steps with
MIPS enabled. A zoomed in figure of salt pulse #3 was shown on the top.
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(a)

(b)

Figure 4.3. Box plot of MS1 percentages in 11 salt pulse steps with MIPS enabled (a) and
disabled (b). Each color of boxes represents one individual salt pulse measurement.
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the rank of a precursor ion divided by the total number of available precursor peaks in a full MS.
Therefore, the higher the percentage is, the deeper measurement can be achieved since precursor
ions with lower abundance have been selected for fragmentation. As shown in Figure 4.3, a
medium MS1 percentage of ~30% was achieved in almost all salt-pulse steps (except ~18% in
the 11th step) with MIPS enabled whereas a percentage of ~18% was obtained with MIPS
disabled. The higher MS1 percentage in the first situation demonstrated that enabling MIPS
allowed for a deeper proteome measurement.

4.3 Informatic considerations for human gut metaproteome
While efforts have been made to optimize and improve the experimental and technical
procedures for gut metaproteome, emphasis should also be put on the bioinformatics steps that
transfer the raw MS/MS data into reliable protein identifications and meaningful biological
information, as depicted in Figure 4.4. The starting point for metaproteomics data analysis is an
extensive experimental dataset(s) of proteolytic peptide masses and fragmentation patterns
generated by high-performance mass spectrometry. The overall informatics process consists of a
number of sequential steps, including metagenome database construction, database searching for
peptide identifications, protein assembly/grouping, and biological information extraction.
4.3.1 Construction of protein sequence database
Depending on the complexity of communities, the size of metaproteomic databases can
range from containing tens of thousands to millions of proteins predicted from a variety of
organisms. Constructing an appropriate database plays an essential role in FDR calculation and
therefore determines the success of confident protein identifications [56]. At present, there are
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Figure 4.4. Informatics workflow for metaproteomics. While there are various options at every
step, the most common route would be preparation of a deep and well-annotated metagenome
from the exact same sample targeted for metaproteome measurement, peptide identifications
based on database searching/filtering/scoring against that matched metagenome, assembly into
protein groups based on parsimony/sequence homology, normalization/statistical analysis, and
finally graphic display of correlations for extraction of biological information.
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essentially three different strategies for metagenome construction that are employed for
metaproteome identifications: a “pseudo-metagenome” consisting of selected complete isolate
genomes (the selection is typically guided by 16S rRNA information of the community) [100], a
related but unmatched metagenome (which can be obtained from a similar community on the
basis of the assumption that they may share most organisms) [72] and a sample-specific
metagenome (which is built on the same sample as in proteomic analysis) [10]. Despite
advancements in genomics leading to higher throughput and decreased costs, metaproteome
database construction is still not trivial and facing significant challenges in the assembly and
prediction of complete proteins. Therefore, many metaproteomics studies are often conducted on
samples lack of metagenome but available for 16S rRNA information. A reference database can
be constructed by concatenating a number of related sequenced isolate genomes and provides a
quick and general functional characterization of the community. One advantage of the reference
database is that selected isolate genomes are generally complete and accurately assembled. An
example of a pseudo-metagenome approach focused on an iterative workflow for database
searching, in which spectra were first searched against a synthetic metagenome comprised of
over 200 intestinal species [100]. Next, a new database was created by blasting the hits from the
first search against MetaHIT repository for homologous sequences. This new database was then
used for a second search and permitted species-specific protein identifications. Clearly, the major
disadvantage of using pseudo-metagenomes is that they do not accurately reflect the actual
genome repertoire, since they lack distinct sequence information inherent to a particular
microbial population. As a result, the identified metaproteome will be biased toward those
organisms included in the database, leading to a skewed representation of the community being
investigated.
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In contrast to the pseudo-metagenome, the accuracy of protein inference increases when a
closely related metagenome is available. Even without being an exact match to a particular
sample, this approach improves the accuracy of protein identifications and has been used for gut
microbiota studies in different humans [72]. In this scenario, the genome is much more reflective
of the sample and thus a wider range of microbial membership can be evaluated. The unmatched
metagenome can be also augmented with isolate genomes, which can generate even more protein
identifications [72].
Of course, the most accurate means to characterize a microbial community involves
employment of high quality matched metagenomes [10, 158]. In the context of the fecal
proteome of two healthy human individuals, a study compared several assembly and gene
finding strategies to increase microbial peptide spectral matching [158]. Overall, searching a
matched metagenome facilitated a significant increase in the total number of assigned spectra,
peptide identifications as well as protein identifications, as compared to the search with a
concatenated database. However, as mentioned previously, there are some challenges in this
approach, particularly the depth and coverage of the sequencing, as well as the accuracy of
assembly and annotation. This may explain why the iterative search workflow with synthetic
metagenomes showed higher spectral identifications when compared to the search with a
matched metagenome.
4.3.2 Impact of metagenome quality and complex on peptide identifications
The completeness, accuracy and size of the metagenome will determine the assessment of
matches between experimental spectra and databased predicted spectra by affecting the threshold
for confident matches. In general, this threshold is controlled and regulated through the
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calculation of FDR [129]. FDR estimate assumes that false positive PSMs are equally likely to
map to either the target or decoy database. However, this assumption can be more problematic
when dealing with metaproteomes. Due to the presence of many incomplete protein fragments in
the metaproteome database, FDR is best and most meaningful to be evaluated at the PSM level.
Moreover, FDR calculates the fractions of false positive assignments and can efficiently assess
the confidence of assignment if the distributions of true and false PSMs can be well
discriminated. However, this discrimination becomes increasingly blurry when the quality of the
database is reduced or the size of the database is too large. Thus, in order to achieve a desirable
FDR, the database search algorithms dynamically increase PSM scoring thresholds, which can
result in an increase in the number of false negatives. To illustrate the importance of database
size and completeness in peptide assignments, we compared the false positive and true positive
PSM distributions for various database qualities and sample complexities (Figures 4.5 and 4.6).
As shown in these figures, better matched databases and lower complexity biological systems
facilitated better differentiation between true and false hits and thus accurately assigned a larger
percentage of acquired fragment ion spectra. These results again stressed the importance of
database quality and complexity with respect to identification sensitivity in metaproteomics.
4.3.3 Quality assessment of tandem mass spectra
Hundreds of thousands of tandem mass spectra are frequently collected in proteomics
experiments. However, a significant number of spectra remain unidentified, especially for
complex biological samples. For example, only ~30% of total collected spectra were identified in
the infant gut metaproteome described in Chapter 3. Although unidentified spectra can be caused
by a variety of reasons, such as poor quality spectra, incomplete database, modifications and
constrained thresholds, the first and critical step of peptide identification is to evaluate the
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(b)

(a)

Figure 4.5. Impact of database quality on peptide identifications. Peptide spectrum matches can
be ranked by MyriMatch Xcorr scores to reveal the distribution of true positive (red) vs. false
positive (gray) identifications in human adult gut microbiome datasets searched with either a
matched metagenome (a) or a pseudo-metagenome assembled from selected microbial isolates
(b). An appropriate Xcorr score threshold (indicated by blue dashed line) is chosen to achieve a 1%
PSM (peptide spectral match) FDR (false discovery rate; defined by the ratio between false
PSMs and total PSMs above the score threshold). The figures reveal that the matched
metagenome better differentiates true vs. false distributions, as evidenced by the higher
percentage of “red identifications” to the right (i.e. higher Xcorrs) of the dashed line. Even
though the pseudo-metagenome likely contains better quality, assembled microbial genomes, the
matched metagenome is more closely linked to the actual environmental sample.
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Figure 4.6. Impact of sample complexity on peptide identifications. Peptide spectrum matches
can be ranked by MyriMatch Xcorr scores to reveal the distribution of true positive (red) vs.
false positive (gray) identifications for samples of a synthetic mixture of six microbial isolates
(all sequenced genomes) (a), a human infant gut microbiome, (b), a human adult gut microbiome
(c), and an environmental soil (d). An appropriate Xcorr score threshold (indicated by blue
dashed line) is chosen to achieve a 1% PSM (peptide spectral match) FDR. The level of true hits
is greatest for the synthetic mixture, since the genomes are compete and well annotated. As the
complexity of the community increases, the ability to separate true and false hits decreases, as
indicated by the superior identification rates in the low complexity infant sample (b) relative to
the higher complexity adult gut sample (c). For (b-d), relevant metagenomes were employed,
although the metagenome of the soil sample was significantly larger (about 1.3 million genes,
which was at least 2X larger than the adult gut microbiome metagenome). This metagenome
could not be assembled to a satisfactory level and thus was highly fragmented, which resulted in
virtually no distinction between true vs. false hits. This attests to the need for not only matched
metagenomes, but well assembled and curated versions, for complex samples.
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(b)

(c)
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quality of MS runs. Several spectral quality assessment tools have been developed recently. For
example, ScanRanker tool assigns quality scores to every tandem mass spectra via sequence
tagging [156]. In general, a high quality spectrum of a peptide is expected to contain a series of
fragment ions, which can be inferred as multiple sequence tags with high scores. Spectra with
higher scores/quality are more likely to be identified in a proteomic study and thus the number of
high quality spectra in the dataset helps reveal the richness of identifiable spectra. This is
potentially useful for metaproteomic studies, in which ScanRanker can be used to determine the
number of unidentified high quality spectra (Figure 4.7). A large portion of unassigned high
score spectra may suggest the incompleteness of a metagenome. Moreover, these spectra can be
further reanalyzed and recovered by other approaches, such as blind modification search or de
novo sequencing [159-161], resulting in new identifications and biological information.
4.3.4 Protein grouping and clustering
As mentioned in the previous chapter, to alleviate the ambiguity associated with shared
peptides, proteins can be clustered into protein groups by sequence homology algorithms. As a
result, shared peptides are found to be unique to a protein group. Before any measurements are
collected, the number of unique peptides can be predicted at the database level and also the
number of unambiguous proteins (likely to be detected with unique peptides) can be calculated.
These numbers will provide an estimation of potentially ambiguous protein rate and to what
degree, these ambiguous assignments will impact the collected data. To illustrate this, the
number of unique peptides was predicted in human database and 21-isolates reference database
constructed in Chapter 3. Since not all peptides are MS-friendly [162], two databases were run
through PeptideSieve (Seattle Proteome Center), a software that calculates the likelihood of
peptides detected by ESI-MudPIT experiments. Only those peptides that were highly possible
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Figure 4.7. Evaluation of ScanRank to determine unidentified high quality spectra. One infant
gut microbiota dataset was identified with MyriMatch. These graphs plot the distribution of
identified (dark red) and unidentified (light red) spectra in deciles by ScanRanker scores. The left
side represents spectra assigned with high ScanRanker quality scores and the right side
represents the low quality spectra.
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(p>0.9) to be detected were retained and analyzed. Scatter plots of total peptides per protein
against unique peptides per protein showed the degree of redundancy for the two tested
proteomes (Figure 4.8). Red dashed line along the diagonal represent the situation where all
peptides are unique, while blue dashed line showed the trend line of observed data. Thus, the
larger the trend line deviated from the diagonal, the higher the redundancy one proteome can
have theoretically. Obviously, human database showed much higher redundancy due to paralogs
present in the genome. Besides the number of unique peptides, it is also interesting to calculate
the number of redundant proteins. For human proteomes, there were 73% (25173 out of 34657)
detectable proteins (containing at least one peptide with p>0.9), and among those proteins, 54%
had more than 95% shared peptides and thus highly redundant. In comparison, 21- isolates had
68% (48234 out of 70969) detectable proteins and only 7% of which were highly redundant.
The goal of protein clustering is to alleviate the ambiguous protein inference by grouping
together those proteins that cannot be differentiated through the measurement and some shared
peptides can be “rescued” and become unique to the protein group after clustering. Therefore,
protein clustering has been recognized as an efficient way to study the shared functional process.
However, in the process of clustering, it is possible that multiple protein identifications are
combined into one identification, which reduces some level of protein resolution and loses the
strain information. As the clustering threshold decreases, more peptides can be “rescued” but
fewer protein groups that contain more memberships will be generated. Therefore, it’s important
to test a range of thresholds to balance the tradeoff between the protein ambiguity and resolution.
As shown in Figure 4.9a, a dramatic collapse (50%) of human proteins was observed when
clustering at 90% while protein groups in 21 isolates were decreased much slower when
lowering the similarity threshold, indicating higher redundancy in the human database and 90%
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(a) Human

(b) 21 isolates

Figure 4.8. Degree of database redundancy. Peptides that were most likely to be detected in an
ESI-MudPIT experiment were predicted using PeptideSieve. For each protein, total number of
predicted peptides and number of unique peptide were plotted. Red dashed line represented that
all predicted peptides were unique and blue dashed line represented the actual trend line of the
data.
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(a)

(b)

Figure 4.9. Determination of similarity threshold. (a) Human (blue line) and 21 isolates (red line)
database were clustered at different sequence similarities and % of original genome sizes were
calculated by total number of protein groups after clustering over total number of proteins in the
original database. (b) Post database searching, number of “rescued” peptides (peptides were nonunique to the database but became unique to a protein group after clustering) were calculated at
different sequence similarities.
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can be an appropriate threshold. Also, we plotted the number of “rescued” peptides at multiple
thresholds for 21 isolates (Figure 4.9b) and found a sharp increase when lowering the threshold
to 85%, which was suggested to be the appropriate threshold. Nevertheless, there are not exact
rules for the threshold, it should be as conservative as possible and more importantly,
considering the objective of the study. For example, if the study focuses on the strain resolved
proteome identifications, 100% may be chosen even though this threshold usually can’t help
unambiguous protein identifications.
4.3.5 Protein quantification
Equally as important as protein identifications, the other challenging task in proteomics is
to accurately quantify and differentiate proteins from different biological samples. Although
various quantification methods have been developed [27], such as metabolic and chemical
labeling, label-free quantitative proteomics has been widely used to compare proteins across
samples because its workflow is straightforward and much less expensive. Label-free
quantification based on MS2 product ion scans is typically performed through two strategies:
spectral counting estimates the number of MS/MS spectra matched to all peptides from a given
protein; and intensity-based MIT that sums up the matched product ion intensities in each MS2
spectrum assigned to a given protein [163]. Here we tested two quantification methods on an
infant gut metaproteome data and found that the quantification by MIT correlated very well with
that using spectral counts (rs = 0.9, Figure 4.10). But MIT presented a greater range of difference
than spectral counts, particularly for those low abundance proteins. For example, a number of
proteins that were quantified with two spectral counts can’t be differentiated if spectral counting
quantification was applied. However, the intensities of these proteins varied from 215 to 220,
providing the greater level of specificity and more accurate protein abundances. More recently,
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Figure 4.10. Comparison of protein MITs with spectral counts. Protein plotted here required at
least one unique peptide. For MIT, a peptide MIT was achieved by summing up the intensities of
all scans that matched to the peptide. MIT of shared peptides were balanced among all shared
proteins. A protein MIT was calculated by summing up all unique peptide MITs and balanced
portions of shared peptides. Protein spectral counts were obtained by summing all unique peptide
spectral counts and balanced spectral counts from shared peptides. The spearman correlation
coefficient of log2 (spectral counts) and log2 (MIT) was 0.9.
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researchers have described that MIT showed good linear response to a range of protein
concentrations but not spectral counts [164]. This indicates that MIT is sensitive to variations of
sample loading amount and useful in the comparison of protein levels relative to units (for
example, protein levels per gram raw material). On the other hand, spectral count is more
tolerant to unequal loading amount, which can be a valuable feature for samples that are difficult
to achieve equal loading amount. From this perspective, spectral counting quantification may be
more robust in metaproteomics studies where the relative abundance of every organism can vary
across samples.

4.4 Conclusions
Although metaproteomics has emerged as a valuable research tool for the investigation
of metabolic activities of complex communities, a careful consideration of both experimental and
informatics components is needed for the successful deployment. We have demonstrated that
considerations of sample preparation and instrumental settings play an important role in
improving the depth and accuracy of proteome measurement. As for informatics component, the
starting point is to evaluate the metagenome quality, complexity and redundancy, since these
properties of the metagenome directly impact the resulting protein identifications. Due to the
redundancy in the metaproteomic data, an effective way for unambiguous protein inference is to
group/cluster proteins with an appropriate threshold that alleviates the ambiguity and provides
each group with meaningful biological information. Finally, an extensive inventory of protein
identities and abundances can be achieved and further translated into metabolic information.
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CHAPTER 5
Metaproteomics of a healthy premature infant gut to access early-life
microbial functionality and host responses

5.1 Introduction
Microbes colonize all internal and external surfaces of the human body and influence all
aspects of human physiology. The largest microbiome locates in the human gastrointestinal tract
(GIT), which is composed of up to 100 trillion microorganisms, comprising thousands of
different species and five million unique genes [57]. Microbes residing in the gut interact with
each other and the host, play important roles in host nutrients through the production of vitamins,
short chain fatty acids (SCFA) and amino acids, regulations of immune system by establishing
immune tolerance to commensal bacteria and immune protection against pathogen, and
maturation and integrity of the intestinal epithelium [165]. Dysbiosis of the gut microbiota has
been linked to many diseases, such as Crohn’s disease [166-168], diabetes [11, 169] and
autoimmune diseases [170]. The establishment of gut microbiota begins during infancy, and
emerging evidence has suggested that this initial colonization may have a life span effect on the
human health [88]. While most recent studies about gut microbiome have revealed the microbial
development of human adults in healthy and diseased state, fewer studies have focused on
understanding the establishment of the microbiota at birth and how microbiota is associated with
infant health and diseases, especially for preterm infants.
Both term and preterm infants were thought be born sterile in the gut, but this has been
challenged by the presence of microbes in the placental and meconium samples [89].
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Immediately after birth, the sterile/near sterile gut of the newborn infant is colonized with
bacteria through the first contact with the mother and the environment. Typically the initial
colonizers of the gut are facultative anaerobes. Within days or weeks, there is a shift from
facultative to obligate anaerobes [171]. The establishment of the microbiota is influenced by
multiple factors, including gestational age, delivery mode, birth weight, diet and exposure to
antibiotics [89, 148, 172]. For example, the microbiota of infants born vaginally resembles the
mother’s vaginal and fecal microbiota whereas infants born by cesarean section develop their
microbiota similar to skin or environmental bacteria [148]. It has also been suggested that Csection delivered infants have lower complexity gut microbial community compared to vaginally
delivered infants [173]. The infant gut undergoes rapid increase in the abundance and diversity
of microbial population during the first a few weeks. Large variations have been observed among
different individuals and also over time within the same individual [89]. After 2.5 ~ 3 years of
life, an infant’s gut microbiome become a stable and adult like microbiome [174]. It remains to
be determined that what factors (host genetics, environment, diet and/or interplay between host
and microbiome) and how these factors determine the path of microbiome development as well
as the influences of different paths on the host health and disease status. This is particularly
critical for premature infants who may have a delayed and aberrant microbiota.
Infants born prematurely are at higher morbidity and mortality risk due to the immature
organ systems that are not properly functional to adapt to the extrauterine life [89]. These infants
are susceptible for inflammation disorders as a result of poorly developed immune system and
prenatal/postnatal events that inappropriately modulate the immunity [89, 175]. Necrotizing
enterocolitis (NEC) is a devastating intestinal inflammatory disease of premature infants,
especially for those born with very low birth weight (500 – 1500 grams) and born prior to 28
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weeks of gestation [176, 177]. NEC typically occurs in the second to third week of life in
premature infants and is characterized by intestinal inflammation and damage, such as mucosal
injury or necrosis. Additional potential risk factors causing NEC may involve in formula feeding,
enteral feeding, blood transfusion and overall health [178]. The role of bacterial colonization in
neonatal NEC has been suggested by a number of observations, including the identification of
pneumatosis intestinalis (gas in the bowel wall) which is most likely produced by intestinal
bacteria, occurrence of outbreaks in hospital, and resolution of inflammation after treatment with
antibiotics [93, 96, 179]. Therefore, recent researches have focused on investigating the
composition of microbial community associated with NEC [180]. A number of bacteria have
been implicated in the pathogenesis of NEC, but none of them has been identified as the
infectious agent [181]. Recently, Raveh-Sadka et al. analyzed gut communities in a number of
premature infants during an outbreak of NEC but however, found no single bacterial strain was
shared among all infants who developed NEC [97]. This may indicate that NEC is not attributed
to a single bacterial strain. Instead, it may be caused by the introduction of a few harmful
bacteria that disrupts the essential activities of commensal microbes in protecting the intestine.
Therefore, better characterizing the functional activity of bacteria during colonization in both
healthy and NEC infants could help understand the role of gut microbiome in the development of
NEC.
Mass spectrometry based metaproteomics approach has been widely used to analyze
communities samples and has emerged as an indispensable tool in investigating the gut
microbiota [10, 99]. Since many challenges still remain, our efforts were made to develop and
optimize the experimental and informatics pipeline for the infant gut microbiome
characterization in previous chapters. It is noted that the onset of NEC usually occurs over a time
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period and therefore a comprehensive interpretation requires multiple time points to capture the
variation prior to the development of NEC. Before getting into the comparisons between the
healthy vs diseased state, we will first focus our study on describing the dynamic functional
profiles for the gut microbiota of a healthy preterm baby over time in this chapter. Metagenomics
information of these samples have been previously analyzed and revealed shifts in bacterial
species, strains, and phage during early colonization. It’s also worth mentioning that nearcomplete genomes were constructed in a few highly abundant organisms, which enabled the indepth proteome characterization.

5.2 Materials and methods
Sample collection. Fecal samples were collected from a healthy (did not develop NEC) preterm
infant (#3) over the first three months (DOL (day of life) 11, 12, 13, 15, 18, 21, 25, 28, 78 and 86)
after birth. This infant was born by C-section at a gestational age of 26 weeks with birth weight
822 grams. The infant was breast milk fed starting from day 4 and withhold on days 7-9 because
of blood transfusions. On day 17, the breast milk was fortified to 24 kcal/oz. The infant received
initial treatment with antibiotics (ampicillin/gentamicin) for the first 7 days of life, vancomycin
on days 51-58 for cellulitis, cefotaxime on days 51-53 and vancomycin/claforan on days 63-65
for sepsis evaluation. Fresh sample were collected using a previously described technique, but
samples 11, 13, and 15 were left in the fridge for 5, 3, and 1 days respectively, whose proteome
might be changed. For days 15 and 21, a second sample (in total two samples) was collected at
different time of the same day. Samples were obtained under an IRB agreement protocol, and
were de-identified before sending to ORNL.
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Sample preparation and measurement. ~0.5 g raw fecal material was prepared by the indirect
double filtering method described in Chapter 3 with modifications. The second filter was not
applied in this study. Obtained peptide samples (50 µg) were analyzed 24 hours with 11 steps via
2D LC-nESI-MS/MS system on LTQ-Orbitrap Elite (Thermo Fisher Scientific, San Jose, CA).
Full scans were acquired at 30k resolution (1 microscan) in the Orbitrap, followed by CID
fragmentation of the 20 most abundant ions (1 microscan). Monoisotopic precursor selection was
enabled. Unassigned charge and charge state +1 were rejected. Dynamic exclusion was enabled
with a mass exclusion width 10 ppm and exclusion duration 30 seconds. Technical replicates
(duplicates) were performed for each sample.
Data processing. A protein database was constructed by combining matched metagenome
collected on multiple days, human protein sequences and common contaminants. All MS/MS
spectra were searched with the Myrimatch version 2.1 algorithm [132] against the constructed
protein database and filtered with IDPicker [135] using the same parameters described in
Chapter 3. Proteins were grouped base on 90% amino acid sequence similarity for human
proteins and 100% similarity for microbial proteins. Spectral counts were balanced between
shared proteins, and normalized by total numbers of all collected MS/MS in each run.
Data analysis. KEGG Orthology (KO) of the metagenome was assigned by KASS (KEGG
Automatic Annotation Server) using single-directional best hit (SBH) method for amino acid
sequence query and KEGG pathways were constructed for both human and microbiome
proteomes using KEGG Mapper (http://www.genome.jp /kegg/tool/map_pathway.html) . The
multidimensional scaling plots (MDS), which measure the similarities among samples, were
performed by the edgeR package [182]. The dataset was normalized based on scaling factors for
library sizes, which were determined using a trimmed mean of M-values (TMM) between
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samples. Hierarchical clustering of microbial proteins were carried out using heatmap.2 function
in R (version 3.1.1) using the moderated log-counts-per-million values calculated by the edgeR
package. Hierarchical clustering of human proteins were performed by JMP Genomics (SAS,
Cary, NC) using log transformed spectral counts. Blast2GO platform [183] was employed to
generate gene ontology (GO) annotations of the metagenome with a BlastP E-value hit filters of
1 × 10−6, an annotation cutoff value of 55, and GO weight of 5. GO terms enrichment was
assessed by employing the Fisher’s exact test and correcting for multiple testing at a cutoff of
FDR<0.05. GO analysis of human proteomes were performed by ClueGO, a Cytoscape plug-in
application that interpret functionally grouped gene ontology annotation networks [184, 185].
Enrichment was calculated by right-sided hypergeometric enrichment tests at a medium network
specificity selection and p-value corrections using the Benjamini-Hochberg method. The selected
GO tree levels were a minimum of 3 and a maximum of 8 while each cluster was set to a
minimum of between 3% and 4% genes. The GO term grouping setting was selected to minimize
GO term redundancy and the highest significance term enriched was used as the representative
term for each functional cluster. Only p-values less than or equal to 0.05 were considered
significantly enriched.

5.3 General overview of metaproteomic datasets
Fecal metaproteomes of a healthy preterm infant were examined on days 11, 12, 13, 15,
18, 21, 25, 28, 78 and 86 after birth by shotgun metaproteomics approach. Up to 111954 spectral
counts, 22779 peptides and 4140 protein groups were identified per run (Table 5.1), revealing
deep proteome measurement for these complex fecal samples. Each sample was measured in
duplicates with high reproducibility (R2 > 0.95). Although biological replicates can have multiple
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Table 5.1. Number of identified peptides, protein groups and MS/MS spectra

Total
Assigned
SpC*

Peptides

Total
Protein
Groups

Human
Protein
Groups

Microbial
Protein
Groups

Total
Protein
Group
SpC

Human
Protein
Group
SpC

Microbial
Protein
Group
SpC

Day11_run1

85602

17104

2643

1781

862

84778

57907

26871

Day11_run2

84056

16457

2600

1759

841

83239

572717

25968

Day12_run1

78589

15165

2666

1597

1069

77450

51425

26025

Day12_run2

74262

12490

2203

1301

902

73421

50101

23320

Day13_run1

80759

11526

2109

960

1149

79672

46986

32686

Day13_run2

77352

10272

2007

909

1098

76320

46892

29428

Day15_1_run1

90513

13237

2462

1239

1223

89844

54466

35374

Day15_1_run2

82444

17430

3138

1636

1502

82471

48805

33666

Day15_2_run1

82764

16367

3025

1660

1365

82004

57116

24888

Day15_2_run2

70144

15444

2833

1610

1223

69560

50136

19424

Day18_run1

111290

22779

4140

1116

3024

110351

35224

75128

Day18_run2

102632

19912

3611

918

2693

101437

33309

68127

Day21_1_run1

96231

22012

3829

1880

1949

95702

57939

37764

Day21_1_run2

93684

20079

3514

1707

1807

93090

55625

37445

Day21_2_run1

48000

10503

2017

767

1250

47653

25153

22500

Day21_2_run2

50563

9901

1970

766

1204

50273

26720

23553

Day25_run1

79003

17770

3495

564

2931

78965

20149

58816

Day25_run2

76006

14960

3004

470

2534

75878

19883

55995

Day28_run1

111017

21079

3683

272

3411

111436

14766

96670

Day28_run2

111954

21308

3758

278

3480

112387

15020

97367

Day78_run1

96468

18497

3253

249

3004

96148

21537

74611

Day78_run2

105730

20457

3562

265

3297

105545

22168

83377

Day86_run1

30877

6147

1212

185

1027

30268

9535

20733

Day86_run2

25235

5398

1080

159

921

24700

8557

16143

*SpC: spectral counts
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meanings according to the context of the study, for example, the same organisms grown under
the same conditions, it is basically impossible to obtain biological replicates for human infant
fecal samples. However, it is still of interest to investigate how different samples collected on the
same day correlate with each other and whether these samples can be treated as biological
replicates. Fecal samples were collected twice on days 15 (samples 15_1 and 15_2) and 21
(samples 21_1 and 21_2), among which only samples 15_1 and 21_1 were analyzed with
metagenomics information. Therefore, the database searching of samples 15_2 and 21_2 was
conducted using unmatched but related metagenome. A Pearson correlation of r = 0.81 was
found between 15_1 and 15_2 while the correlation between 21_1 and 21_2 was r = 0.52,
indicating that the gut microbiome could change greatly within a day. This was also recognized
by other studies that showed rapid and reproducible alteration of human gut microbiome by
dietary interventions [67].
Human and microbial proteins were both monitored, providing a total of 9318 microbial
and 3250 human protein groups across all time points (Figure 5.1 (a)). As the time increases, it
was observed that the number of identified microbial protein groups increased while that of
human protein groups decreased, mainly due to the increasing complexity of microbial
composition revealed by metagenomic information. As microbial proteins became more
abundant, the measuring depth of human proteins decreased and remained stable until after day
28, with ~ 200 identified human protein groups. This trend was also observed in the percentage
of human/microbial relative abundance, where human proteins accounted for ~70% of total
spectral counts at early time points and this percentage decreased to ~30% by day 25 (Figure 5.1
(b)). It was also noticed that less proteins and spectral counts were identified in samples 21_2
and 86. Thus, total number of collected spectra and high quality spectra were evaluated in these
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(a)

(b)

Figure 5.1. Number of human and microbial protein groups identified (a) and relative abundance
of human/microbial spectra (b) over time.
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two samples and found to be comparable with other samples, suggesting that the variation was
less likely due to the low quality MS measurements but rather the incompleteness of the database
(Figure 5.2).
Multidimensional scaling (MDS) was applied to assess similarities and differences of the
protein expression across all time points for both human (Figure 5.3 (a)) and microbial proteins
(Figure 5.3 (b)). To filter out low abundance proteins, total identified proteins were filtered based
on having 100 counts per million (cpm) for at least one sample/library, which reduced the
number of tested proteins from 12568 to 6137. After filtering, the new library size was compared
with the original one and more than 95% of total assigned spectral counts were retained for each
library, which indicated that half identified proteins had low number of spectral counts across all
samples. MDS plotted 12 samples on a two-dimensional scatterplot and the distances
approximated the protein abundance differences between the samples. It was observed that
technical replicates were clustered together, which means that replicates were highly
reproducible. In contrast to the high similarity in replicates, proteomes from different days were
dissimilar and separated from each other. When only looking at microbial proteins, samples were
separated in the order of time course and samples from adjacent days were clustered tightly.
However, the pattern of human proteins was slightly different; for example, day 13 was distant
from day 11 and 12, but clustered together with day 25. Although human and microbial proteins
did not follow the same pattern, an obvious separation in day 25 on x-axis was observed for both
of them, suggesting a possible major shift in the microbial functionality and corresponding host
response during the time.
As microbial community composition shift rapidly over time, different sets of proteins
were detected in each sample. The frequencies of identified proteins in 12 samples were
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Figure 5.2. Number of total collected spectra and high quality spectra for each sample. High
quality spectra were determined using ScanRanker tool.
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(a)

(b)

Figure 5.3. Multidimensional scaling (MDS) plot of 12 fecal proteomes for microbial proteins (a)
and human proteins (b). MDS analysis was performed using the edgeR function plotMDS with
log fold-change method estimated on spectral counts (normalized to library size). Color
represented different fecal samples and technical replicates were labeled as the same color.
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calculated in Table 5.2. Surprisingly, only 0.9% (109) of total identified proteins (12568) were
identified in all 12 samples, including 94 human proteins and 15 microbial proteins. It is
significant that over half total proteins were only identified once or twice and this percentage of
uncommonly identified proteins was higher in microbial proteins (60%) as compared to human
proteins (40%). A large number of unshared proteins made it challenging to compare changes in
protein abundances across all time points.

5.4 Metagenome - metaproteome comparisons
One of the most important considerations for metaproteomic experiments is the
biodiversity of the sample being analyzed. How many organisms are present and their relative
abundance directly affect the proteome coverage of a single organism. A typical 24-h LC
MS/MS experiment usually identifies a few thousand proteins regardless the proteome size, due
to the constrained dynamic range and duty cycle of the mass spectrometer. Therefore, more
complex community yields lower average proteome coverage and species with higher abundance
or more active functionality tend to have a larger percentage of proteome that can be detected.
Integrating strain-resolved metagenomics with deep metaproteomic measurements, we were able
to characterize the proteome coverage of different species and strains across time, as shown in
Figure 5.4. Since not all predicted proteins are expressed under one condition, a typical proteome
of a single isolate can identify approximately 60% of the predicted proteome. Here, in total
across all samples, up to 45% of the predicted proteins for an individual organism were obtained.
As shown in the “TS” column in the figure, species were ranked according to the proteome
coverage, with Staphylococcus phage the highest and Veillonella sp. the lowest percentage. Due
to the rapid shift in the microbial composition over time, proteome specific to dominant species
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Table 5.2. Frequencies of human and microbial proteins identified across time

Frequencies

# of
proteins

Total

# of
proteins

Human

# of

Microbial

proteins

proteins

proteins

(%)

(%)

1

4308

34.3

863

26.6

3445

37

2

2551

20.3

450

13.8

2101

22.5

3

1833

14.6

330

10.2

1503

16.1

4

1000

8

245

7.5

755

8.1

5

682

5.4

265

8.2

417

4.5

6

697

5.5

220

6.8

477

5.1

7

466

3.7

212

6.5

254

2.7

8

340

2.7

210

6.5

130

1.4

9

263

2.1

160

4.9

103

1.1

10

196

1.6

114

3.5

82

0.9

11

123

1

87

2.7

36

0.4

12

109

0.9

94

2.9

15

0.2

Total

12568

100

3250

100

9318

100
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Figure 5.4. Organism-specific proteome coverage. Percentage of identified proteome was plotted for all microbial organisms at each
time point being analyzed. Total proteome coverage across all samples was also shown in the last column. Different colors represented
different species and figure legend was arranged in descending order of the proteome coverage. Species with highest proteome
coverage within a sample was labeled on top of the figure. (Provided by Chris Brown)
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and strains also shifted (as labeled on top of Figure 5.4). At early time points (days 11-13), the
dominant proteome belonged to Enterococcus faecalis and this shifted to Staphylococcus phage,
Propionibacterium sp., Veillonella sp., Streptococcus lutetiensis and Escherichia coli during the
later time course.
To further investigate the activity of microbial community members, relative protein
abundance was compared by assigning proteomic data to genomes (Figure 5.5 (b)). At days 11,
12, 13 and 15, proteomic data confirmed the dominance of Enterococcus faecalis and
Staphylococus phage based on the relative abundance observed in the metagenomics data.
Intriguingly, apparent differences were observed between the genomic and proteomic patterns on
certain days, suggesting a few species that were more active in spite of low abundance, such as
Propionibacterium sp. in day 18, Clostridium sp. and Streptococcus lutetiensis in day 25. By day
28, Escherichia phage began to increase their cell abundance, but however, this trend wasn’t
represented by their proteome abundances. The most active species in days 78 and 86 were
recognized as E. coli, comprising 60% of relative protein abundances. These findings could have
significant impacts on our understanding of dominant organism metabolic activities.

5.5 Global metabolic pathways of human proteome and gut metaproteome
To globally explore the metabolic activities in the infant gut microbiome, we next
characterized and visualized microbial and human functionalities through KEGG pathways [186].
Figure 5.6 showed human proteome and gut metaproteome on a global metabolic map, where
green lines indicated pathways identified by human proteins (only), red lines indicated pathways
identified by microbial proteins (only) and blue lines indicated pathways identified by both. We
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Figure 5.5. Pattern of changes in microbial abundance (a) and protein abundance (b). Relative
proportion of reads (a) and summed spectral counts (b) of all proteins for all microbial organisms
were plotted across time. (Provided by Chris Brown)
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Figure 5.6. KEGG pathways mapping for human proteome and human gut metaproteome. Both human and microbial proteomes were
mapped on KEGG pathways. Human proteome-only pathways were colored in green whereas microbial proteome-only pathways were
colored in red. Overlapped pathways were colored in blue.
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observed that pathways involving in glycolysis, citrate cycle, oxidative phosphorylation, fatty
acid biosynthesis and nucleotide metabolism were commonly possessed by both human and
microbiome. These are core metabolisms for both human and microbial communities, which
support their respective cell growth and maintenance. However, thiamine (vitamin (V) B1),
riboflavin (VB2), cobalamin (VB12) biotin (VB7), folate (VB9) and lipopolysaccharide (LPS)
metabolisms were only found in the gut metaproteome, whereas pathways involving in tight
junctions, regulation of actin cytoskeleton, mucin type O-glycan biosynthesis, and complement
and coagulation cascades were only shown in the human proteome.
Gut bacteria synthesize B vitamins that are essential nutritional factors for human,
especially the gut health [64]. Various types of vitamin B production were detected in the early
bacterial colonization of the infant gut, supporting human gut nutrients. On the other hand, in
response to the bacterial colonization, human host express tight junctions, actin cytoskeleton and
mucins that play pivotal roles in the integrity and barrier properties of mucosal epithelial layers
[187]. Dysbiosis of the intestinal mucosal barrier can lead to the pathological bacterial
translocation and the initiation of an inflammatory response in the intestine. In addition, bacterial
LPS and human host complement system have been suggested participating in the maturation of
human innate immunity [188, 189]. Studies have also suggested that the premature infants are
predisposed to intestinal inflammation due to the immature response to bacteria and therefore
this initial interaction is potentially important in the development and maturation of host immune
system. Overall, these observations have demonstrated that human host and gut bacteria begin to
cooperate on metabolic activities during infancy, which benefit each other and initiate the
establishment of a mature and healthy gut though the gut microbiome-host metabolic crosstalk.
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5.6 Microbial functional characterization
To explore the establishment and changes of microbial metabolic activities over time, the
metagenome was annotated with gene ontology (GO) information using the Blast2GO platform.
Of 38,192 protein sequences predicted from the metagenome, 27,286 sequences were associated
with at least one GO term. Of 9,318 microbial proteins identified from 12 samples, 8,307
proteins were annotated with top GO terms shown in Figure 5.7. The analysis showed that the
microbiome mainly involved in the biological processes of metabolic, cellular, localization and
response to stimulus processes, the molecular functions of binding, catalytic and transporter, and
the components of cell and membrane part.
To further investigate the pattern of microbial proteins over the time course, protein
abundances were analyzed using hierarchical clustering, revealing four clusters with similar
expression patterns (Figure 5.8): cluster I (days 11, 12 and 13), cluster II (days 15_1, 15_2, 18
and 21_1), cluster III (days 21_1 and 25), and cluster IV (days 28, 78 and 86). It was noted that
technical replicates showed high similarity and samples from adjacent time points were closely
clustered. However, two samples collected on day 21 showed notably different expression
profiles, suggesting major changes occurred between the two samples and also emphasizing the
need for high-resolution sampling. Therefore, we compared the relative protein abundance of
two samples and found out that the introduction of a new dominant colonizer – Clostridium sp.
in the second sample was mainly responsible for the changes (Figure 5.9), although the cause of
the shift wasn’t clear. It was possible that the colonization of Clostridium sp. disrupted the
metabolism of other bacteria and therefore significantly impacted their protein expression
profiles. An obvious separation observed at day 25 in previous MDS results might be also due to
this dominant colonization of Clostridium sp.
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Figure 5.7. Microbiome GO term distributions at level 3 of biological process (BP), molecular
function (MF), and cellular component (CC).
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Cluster IV

Cluster III

Cluster I

Cluster II

Figure 5.8. Hierarchical clustering of microbial proteins. 6137/12568 total detected microbial
proteins were included based on having 100 counts per million (cpm) for at least one
sample/library. The dataset was normalized based on scaling factors for library sizes. Heatmap
was generated using moderated log-counts-per-million (log2 counts-per-million).
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Figure 5.9. Comparisons of relative protein abundance in two samples collected on the same day.
Relative protein abundance was calculated for two samples from day 21. The relative abundance
of Clostridium sp. (as labeled in the figure) was found dramatically different between two
samples.
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GO enrichment analysis of identified proteins was performed for each cluster by using
Fisher’s Exact Test with Multiple Testing Correction of FDR (Benjamini and Hochberg) at a
cutoff of 0.05 (Table 5.3). Total microbial proteins identified from all 12 samples were used as
reference and enriched GO terms were reduced to most specific terms. Glycolytic process and
translation were enriched in all four clusters as energy production and protein synthesis are
fundamentally important in supporting bacterial cell growth. Phosphotransferase system (PTS)
including glucose/fructose/mannose/lactose specific components, was significantly enriched in
cluster I. PTS is a bacterial-specific method for transporting sugars into cell using the energy
source from phosphoenolpyruvate. It was found to be increased in infants fed with exclusive
breast milk as compared to non-exclusively breastfed infants [190]. Enrichment of PTS may
indicate an increasing processing of carbohydrates in the early time course.
Enrichments in cobalamin, purine (particularly GMP) and pyrimidine (particularly UMP)
biosynthetic process were observed in cluster III. Vitamin B12 (cobalamin) production is only
found in bacteria and archaea, and is an essential cofactor for anti-inflammation and neurological
function [191]. Previous studies have observed a decrease in the cobalamin synthesis in patients
with inflammatory bowel disease (IBD) [192] and therefore, VB12 production may play key
roles in the early community colonization. Glutamine metabolic process was also enriched in
cluster III, providing nitrogen donor for the synthesis of purine and pyrimidine nucleotides,
which play important roles in cell signaling, energy metabolism and nucleic acids (DNA and
RNA) formation.
Anaerobic respiration was significantly enriched in the late time course (cluster IV).
Although aerobic respiration wasn’t enriched in the entire period, proteins involved in TCA
cycle, electron transport chain and terminal oxidase, such as NADH: ubiquinone oxidoreductase,
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Table 5.3. Enriched BP GO terms among different clusters
Cluster

Term

FDR

P-Value

GO:0006096

glycolytic process
phosphoenolpyruvatedependent sugar
phosphotransferase
system
translation
carbohydrate
transmembrane
transport
protein unfolding
translation
glycolytic process
tRNA aminoacylation
for protein translation
glycolytic process
cobalamin
biosynthetic process
purine ribonucleoside
biosynthetic process
ATP hydrolysis
coupled proton
transport
GMP biosynthetic
process
UMP biosynthetic
process
glutamine metabolic
process
glucose metabolic
process
regulation of
translational fidelity
translation
glycolytic process
response to heat
cellular carbohydrate
metabolic process
cellular biogenic
amine catabolic
process
biofilm formation

9.09E-05

1.59E-07

2.21E-04

1.07E-06

50

149

2.41E-04

1.22E-06

190

804

5.47E-04

3.68E-06

42

122

3.03E-02
1.62E-06
5.39E-03

5.53E-04
3.49E-10
4.54E-05

6
445
89

8
804
145

5.54E-11

2.46E-13

135

215

3.29E-09

2.80E-11

95

145

8.30E-04

1.81E-05

32

46

2.38E-03

6.00E-05

99

189

5.77E-03

1.59E-04

25

36

8.36E-03

2.42E-04

17

22

9.94E-03

3.05E-04

43

73

2.27E-02

7.80E-04

48

86

2.27E-02

7.98E-04

54

99

2.88E-02

1.03E-03

29

47

1.37E-06
2.56E-05
5.89E-05

1.24E-08
3.81E-07
9.67E-07

554
115
47

804
145
52

1.17E-04

1.97E-06

236

328

9.58E-04

2.01E-05

21

21

5.54E-03

1.58E-04

17

17

GO:0009401
Cluster
GO:0006412
1
GO:0034219
GO:0043335
Cluster GO:0006412
2
GO:0006096
GO:0006418
GO:0006096
GO:0009236
GO:0046129
GO:0015991
Cluster
3

# of
# of
identified total
51
145

GO-ID

GO:0006177
GO:0006222
GO:0006541
GO:0006006
GO:0006450
GO:0006412
GO:0006096
GO:0009408

Cluster GO:0044262
4
GO:0042402
GO:0042710
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Table 5.3. Continued
Cluster

GO-ID
GO:0070887
GO:0006979
GO:0046677
GO:0051172
GO:0019541
GO:0009062
GO:0019320

GO:0015949
GO:0009061
Cluster GO:0006066
4
GO:0033036
GO:1901616
GO:0034310
GO:0006457
GO:0045892
GO:0009267
GO:0009893
GO:0034622
GO:0006970

Term
cellular response to
chemical stimulus
response to oxidative
stress
response to antibiotic
negative regulation of
nitrogen compound
metabolic process
propionate metabolic
process
fatty acid catabolic
process
hexose catabolic
process
nucleobasecontaining small
molecule
interconversion
anaerobic respiration
alcohol metabolic
process
macromolecule
localization
organic hydroxy
compound catabolic
process
primary alcohol
catabolic process
protein folding
negative regulation of
transcription, DNAtemplated
cellular response to
starvation
positive regulation of
metabolic process
cellular
macromolecular
complex assembly
response to osmotic
stress
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# of
# of
identified total

FDR

P-Value

5.90E-03

1.74E-04

45

54

7.46E-03

2.28E-04

70

90

7.97E-03

2.45E-04

44

53

8.35E-03

2.63E-04

76

99

8.35E-03

2.65E-04

16

16

8.35E-03

2.65E-04

16

16

1.31E-02

4.32E-04

26

29

1.34E-02

4.44E-04

15

15

1.45E-02

4.89E-04

19

20

1.49E-02

5.06E-04

86

115

1.84E-02

6.51E-04

99

135

1.88E-02

6.69E-04

41

50

2.07E-02

7.43E-04

14

14

2.15E-02

7.83E-04

106

146

2.58E-02

9.55E-04

56

72

3.27E-02

1.24E-03

13

13

3.47E-02

1.33E-03

34

41

4.01E-02

1.56E-03

31

37

4.97E-02

1.97E-03

16

17

succinate dehydrogenase, cytochrome c oxidase, were identified throughout the dataset,
indicating aerobic growth pathway was continuously active during the colonization. Proteins
participating in the anaerobic respiration were identified in cluster IV, for example fumarate,
dimethyl sulfoxide and nitrate reductase, suggesting that the gut microbiome shifted to
facultative anaerobic state in the late time period as the availability of oxygen decreased.
Enriched propionate metabolic process, particularly the anaerobic degradation of L-threonine to
propionate by L-threonine dehydratase catabolic TdcB and pyruvate formate-lyase (PFL) – like
enzyme TdcE, was also strong evidence for the anaerobic respiration of the community.
Another GO term enriched in cluster IV was hexose catabolic process, resulting in the
breakdown of hexose, for example fucose, rhamnose, mannose and galactose. In particular,
proteins such as fucose/rhamnose isomerase, fuculokinase, and fucose/rhammulose phosphate
aldolase were detected for fucose and rhamnose degradation, which might be further converted
to propionate. Propionate is a SCFA that has potential anti-inflammatory function and maintains
human gut health [193]. Oligosaccharides are major components of human milk and can be
digested into SCFA by intestinal bacteria. SFCA provides energy for intestinal epithelial cells
and lower intestinal pH thus reducing potential pathogens. However, overproduction of SCFA
has also been suggested in the pathogenesis of NEC in premature infants due to the excessively
produced SCFA that can’t be absorbed promptly and injure the vulnerable intestinal mucosa
[194]. Besides propionate, acetate and butyrate are two other principal SCFAs produced by gut
microbiota. The fermentation processes of these two SCFAs were not enriched in our study, but
acetate kinase, butyryl-CoA dehydrogenase, butyrate kinase were detected in days 25-86, and
days 21-28 respectively.
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Interestingly, a series of responses to stimulus, heat, oxidative stress, antibiotics,
starvation and osmotic stress were enriched in cluster IV, suggesting the community was under
various environmental stresses and adapted to the changing conditions. As observed in the
metagenomics information, there was an Escherichia phage dominating the gut microbiota
during this time period. Phage shock protein was detected in response to the phage infection and
might play significant roles in bacterial survival for the competition of limited nutrients and
energy [195]. Additionally, heat stress and reactive oxygen species (ROS) generated in the host
intestine during inflammation can activate bacterial stress response and induce the expression of
protective antioxidant proteins [196]. Indeed, many antioxidant proteins such as superoxide
dismutase, alkyl hydroperoxide reductase, catalase, thioredoxin reductase, glutathione peroxidase
and peroxiredoxin were abundantly identified. Studies have also shown that bacteria can form
biofilm in response to environmental stresses [196]. The formation of biofilm allows bacteria to
grow in close association with host cells and more importantly, provides bacteria resistance to
antimicrobials. Therefore, enrichment of biofilm formation process in this cluster might also be
raised by the bacterial stress response.

5.7 Human host response changing across time
Although a small number of proteins were shared for all samples, 63 human proteins
were

identified

in

all

samples

across

time.

David

Bioinformatics

Resources

(http://david.abcc.ncifcrf.gov/home.jsp) was employed to investigate the functionality of these
core proteins. Activities involved in defense response, inflammatory response and acute
inflammatory response were enriched, suggesting that early life gut maintains a tuned
inflammation that is important to the interaction between human host and gut microbes. Top 20
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abundant proteins were shown in Table 5.4. Lactotransferrin (LTF) was the most abundant
protein throughout all samples. As the major whey in human milk, LTF exhibits antibacterial
activity and may provide benefits in the prevention of NEC in premature neonates [197].
Proteins related to digestion, such as chymotrypsin-C (CTRC) and chymotrypsin-like elastase
family (CELA3A/3B) were found among the most abundant proteins. Other abundant proteins
were involved in gut mucosal barrier protection, such as intelectins (ITLN1, ITLN2) that
recognize pathogen-associated glycans [198] and intestinal alkaline phosphatase (ALPI)
dephosphorylating bacterial LPS [199]. Secretory IgA present in mucosal surface potentially
contribute to gut mucosal defense and its transport across epithelial cells is dependent on the
polymeric immunoglobulin receptor (PIGR), which was also abundant in these fecal samples
[200]. In addition, IgG Fc-binding protein (FCGBP) and calcium-activated chloride channel
regulator (CLCA1) are significantly related to the production and maintenance of the mucosal
structure [201]. Also, complement C3, S100 calcium binding protein A9 (S100A9) and
glycoprotein deleted in malignant brain tumors 1 (DMBT1), also known as glycoprotein 340 (gp340) may participate in the innate immune response in the intestine [202, 203].
To further investigate the expression pattern of human proteins over the time course,
human proteins were hierarchically clustered using protein abundance and 10 clusters were
identified (Figure 5.10). Each cluster was enriched for Gene Ontology using David
Bioinformatics Resources [204]. In general, human proteins were more abundant in the first
month (before day21) than in later time points due to the increasing microbial colonization. No
terms were enriched in Cluster #1 and #9 probably due to a small number of proteins in these
two clusters. Cytoskeleton organization was enriched in Cluster #10 (containing proteins mainly
predominant in days 11 and 12), suggesting the early development of the intestinal epithelial
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Table 5.4. Top 20 abundant human proteins in 12 fecal samples
Gene

Protein description

symbol

Summed
Spectral counts

LTF

Lactotransferrin

95440.46

FCGBP

IgGFc-binding protein

57425.85

CLCA1

Calcium-activated chloride channel regulator

56090.18

CTRC

Chymotrypsin-C

23883.97

DMBT1

Deleted in malignant brain tumors-1

21064.67

CELA3B

Chymotrypsin-like elastase family

18633.93

PIGR

Polymeric immunoglobulin receptor

17731.18

IGHA1

Immunoglobulin heavy constant alpha-1

15774.32

ALPI

Intestinal alkaline phosphatase

15151.16

C3

Complement C3

12527.15

ITLN1

Intelectin-1

10702.16

ALB

Serum albumin

10544.29

MME

Membrane metallo-endopeptidase

8914.46

XDH

Xanthine dehydrogenase

8525.57

VDAC1

Voltage-dependent anion channel-1

7391.13

ACTA1

actin, alpha-1, skeletal muscle

7300.23

SERPINA1

alpha-1 antitrypsin

7096.47

MTTP

Microsomal triglyceride transfer protein

6378.62

S100A9

S100 calcium binding protein A9

6172.59

ITLN2

Intelectin-2

5735.22
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Figure 5.10. Changes of human proteome across time. Proteins were hierarchically clustered
based on protein abundance changes. Each cluster was enriched for GO functions with p value
less than 0.01.
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barrier, which prevents penetration of pathogenic microbes into the mucosa and submucosa.
Complement activation and acute inflammation response were observed in Cluster #5
(containing proteins more abundant in days 13, 15 and 18), suggesting infection might occur
during these days.
We employed ClueGO, a Cytoscape plug-in that provides representative GO terms for a
large set of genes, to explore primary functions of human proteins in response to microbial
colonization across the time course. Top 200 abundant human proteins of each sample were
analyzed and enriched for GO terms and top 5 significantly enriched terms were listed in Figure
5.11. Most of terms contributed to human cell growth and activities such as carbohydrate
metabolism and oxidation-reduction process, especially at early time points. Interestingly, almost
all terms enriched in days 28, 78 and 86 were involved in inflammatory responses to microbes,
which might give an explanation to bacterial stress responses observed in the late phase. The
inflammation produces antibacterials, elevated ROS and heat that help the host compete with and
defend pathogens.

5.8 Conclusions
By employing previously established high-performance mass spectrometry based
metaproteomics approach, we achieved deep proteome measurement for both human and
microbial proteins in a longitudinal study of a healthy infant gut microbiome. We identified a
total of 9318 microbial and 3250 human protein groups from 12 fecal samples across all time
points. It was demonstrated that human proteins were relatively abundant in early time points,
and then reduced as microbes colonized rapidly and the complexity of microbial composition
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Figure 5.11. GO enrichment of human proteome over time. Top 200 abundant human proteins
were subjected for GO enrichment. Pie charts showed all significantly representative terms and
the size/area of the slice represented the significance of a GO term that was enriched. TOP 5
significantly enriched GO terms were listed out.

137

138

increased. Until about one month, the number of human proteins remained stable. The organismspecific pattern of microbial protein abundance was different from that of their genome
abundance, indicating that a few species were functionally active despite low abundance and thus
emphasizing the role of proteomic measurements in the functional characterization.
Starting from the infancy, human and microbes cooperated on metabolic activities in the
development of gut and the maturation of immune system. Four clusters/phases were identified
based on the protein expression pattern of the microbiome. Major functional shift might be
related to the transition of community respiratory mode from aerobic to facultative anaerobic.
Core metabolism of microbial community established early in support of microbial cell growth
and maintenance. As the complexity increased, more activities such as vitamin production and
short chain fatty acid metabolism were observed. It seemed that the community went through
environmental stresses during the late phase, possibly raised by the phage infection or host
inflammatory responses. On the other hand, in response to the microbial colonization, the first
(epithelial barrier) and the second (innate immunity) line of human immune defense was under
development. The complement activation and inflammatory responses indicated in certain days
suggested that a possible infection occurred.
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CHAPTER 6
Characterization of temporal and inter-individual functional differences in
infant gut microbiome by metaproteomics approach

6.1 Introduction
Premature infants may face a number of health problems including breathing and
respiratory difficulties, feeding and digestive problems and neurological and psychiatric
problems, due to underdeveloped organs and systems. As compared to term infants, premature
infants typically harbor delayed and less complex microbial communities [89]. Although not
fully understood, the initial colonization has been related to a number of factors, for example,
gestational age, birth weight, delivery mode, feeding, use of antibiotics, and host health status
[89]. Therefore, huge variations of microbial composition have been observed among premature
infants. It has been reported that NEC and sepsis, conditions primarily seen in premature infants,
can result in differential microbiome development in premature infants. However, no single
species or microbial pattern has been identified as causative agent [176].
In Chapter 5, we have demonstrated that microbial metaproteomics provided the ability
to characterize metabolic activities for both the community and human host at a remarkably deep
level in a healthy premature infant. To further explore inter-individual viabilities and possible
functions that are associated with NEC, in this chapter, we will include three more premature
infants, including two infants from a triplet set (one developed NEC and didn’t survive, one
didn’t develop NEC but had severe sepsis) and one healthy infant co-hospitalized with the two
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above infants. We aimed to explore the longitudinal and individual functional variations in the
gut microbiome and host response among infants.

6.2 Materials and methods
Sample collection. In addition to the infant #3, fecal samples were collected from three more
preterm infants (#19, #21 and #23) over the first three months after birth. Infants #19 and #21
were two infants from triplets, among which, #19 developed severe sepsis but not NEC while
#21 developed NEC and died from NEC totalis. Infant #23 was co-hospitalized with infants #19
and #21, who was healthy aside from some mild lung disease. Additional medical details of four
infants were shown in Table 6.1. Fecal samples from infant #19 (on days 12, 16, 20, 26, 31, 38
and 56), infant #21 (on days 13, 18, 21, 24, 27 and 30), and infant #23 (on days 15, 18, 21, 34, 50)
were collected for metaporteomics analysis.
Sample preparation and measurement. Sample preparation and proteomic measurements were
performed using the same methods described in Chapter 5.
Data processing and analysis. Protein database were constructed for each individual infant by
combining proteins predicted from sequenced metagenome, human proteins and contaminants.
All database searching, peptide matching and protein inference were processed by the same
methods described in Chapter 5. Data were further analyzed using edgeR package [182], KEGG
database [186], and Blast2GO [183] with parameters also described in the previous chapter. The
Venn diagram was generated using the Venny tool. (http://bioinfogp.cnb.csic.es/tools/venny/
index.html)
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Table 6.1. Summary of infant medical information
Infants

#3

#19

#21

#23

Gestational
age (weeks)

26

24

24

27

Gender

Female

Female

Female

Female

Delivery mode

C-section

C-section

C-section

Vaginal

Birth weight
(g)

822

731

697

875

Feeding

Breast milk

Combination

Breast milk

Breast milk

Health status

Healthy

Sepsis

NEC and died

Healthy

Initial 7-day
treatment with
Ampicillin/
Gentamici; Day
51-63 with
Vancomycin
and Cefotaxime

Initial 7-day
treatment with
Ampicillin/
Gentamici; Day
23-31 with
Vancomycin,
Claforan,
Nafcillin and
Gentamycin

Initial 7-day
treatment with
Ampicillin/
Gentamici; Day
24-32 with
Gentamycin

Initial 7-day
treatment
with
Ampicillin/
Gentamici

Antibiotics
use
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6.3 General overview of metaproteomic datasets
Fecal metaproteomes of three more preterm infants (#19, #21 and #23) were measured on
multiple time points by metaproteomics approach (Figure 6.1). A total of 9665 (7397 microbial
and 2268 human), 7091 (6349 microbial and 742 human), and 11649 (10330 microbial and 1319
human) protein groups were identified for infant 19, 21 and 23 respectively. In the proteomes of
baby 19, we observed an increasing microbial load and a decrease of identified human proteins
over time, a similar trend as shown in baby 3, with the exception of a dramatic decrease of
microbial proteins at day 26. This was coincided with the antibiotics use at day 26, suggesting
that the antibiotics effectively suppressed or removed the microbiota. However, proteomes of
baby 21 didn’t follow this pattern but showed relatively stable number of identified human and
microbial proteins. In addition, the number of human proteins was much lower than microbial
proteins across the time. Although the number of human proteins was also less than microbial
proteins in baby 23, it decreased as the community complexity increased. We also examined the
relative abundance between the human and microbiome in all infants across the time course
(Figure 6.2) and similar trends were observed in the relative abundance as in the number of
identified proteins.
To discern the temporal development of human and microbial proteins among infants, we
plotted samples in two dimensions using the multidimensional scaling (MDS) (Figure 6.3 and
6.4). Technical replicates were overlapped with each other, indicating the high reproducibility.
For microbial proteins, in general, samples were separated from each other according to the
temporal order. In the infant #19, days 16, 20, 31 and 38 were closely plotted but distant from
days 12 and 56, which were the first and last day of the time course. However, day 26 was far
away from any other days, might be related to the use of antibiotics. Interestingly, after the
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Figure 6.1. Number of identified human (blue) and microbial (red) protein groups of four infants
over time. The number indicated in the figure included protein groups detected from both
duplicate runs.
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Figure 6.2. Relative abundance of human (blue) and microbial (red) protein groups of four
infants over time. Spectral counts were normalized by the number of total collected spectra and
averaged between duplicate runs.
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Infant #19

Infant #21

Infant #23

Figure 6.3. MDS plots of microbial proteins for infants #19, #21 and #23. MDS analysis was
performed using the edgeR function plotMDS with log fold-change method estimated on spectral
counts (normalized to library size). Different colors represented different fecal samples and
technical replicates were labeled as the same color.
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Figure 6.4. MDS plots of human proteins for infants #19, #21 and #23. MDS analysis was
performed using the edgeR function plotMDS with log fold-change method estimated on spectral
counts (normalized to library size).
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antibiotics treatment, the microbiome seemed to be restored, as day 31 was back to where was
close to day 20. In the infant #21, days 21, 24 and 27 were clustered together and separated from
rest days, while in the infant #23, days 15, 18 and 21 were more similar. Also, we examined the
similarities/differences of human proteins for all infants, including infant #3 who was analyzed
in the previous chapter. For infants #3, #19 and #23, days were scattered but did not follow the
pattern seen in microbial proteins. For example, day 26 of infant #19 was dramatically different
from day 20 of infant #19 in the microbiome, but human proteomes of these two samples were
very similar. For these three infants, human proteomes from early time points were different
from each other but relatively similar to samples from the same infant. For example, days 15, 18
and 21 of infant #3, days 12 and 16 of infant #19, and days 15 and 18 of infant #23 were closely
clustered. It was also very interesting to observe that human proteomes of late time points in
these three infants were almost overlapped, including day 86 of infant #3, day 56 of infant #19
and days 34 and 50 of infant #23. Intriguingly, all human proteomes of infant #21 were clustered
together and separated from all other samples despite changes observed in the microbiome.
Noted that infant #21 was the only infant who developed NEC.

6.4 Microbial community profile
To further survey the microbial community, we performed phylogenic assignments and
compared the relative abundance of the community based on metagenomics reads and protein
abundance (Figure 6.5). Proteins were identified in 25, 18, 12, and 29 different species/strains for
infants #3, #19, #21 and #23 respectively, showing that microbiomes of infant #19 and #21 were
less complex. Microbial composition was largely different and Enterococcus faecalis was the
only species that was shared by all infants. However, a number of species were shared between
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Figure 6.5. Pattern of changes in microbial abundance (a, b and e) and protein abundance (c, d
and f) for infants #19, #21 and #23. Relative abundance of microbial community was based on
mapping metagenome sequencing reads to reconstructed genomes. Activity of microbial
community members was based on assignment of proteomic data to genomes. Most abundant
species/strains based on metagenomes or metaproteomes were highlighted for every sample. The
blue brackets indicate that antibiotics were administered.
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(a) Infant #19 microbial abundance

(b) Infant #21 microbial abundance

(c) Infant #19 microbial activity

(d) Infant #21 microbial activity
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(e) Infant #23 microbial abundance

(f) Infant #23 microbial activity
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the twin baby 19 and 21, such as Staphyloccoccus aureus, Enterobacter cloacae, Klebsiella
oxytoca and Haemophilus parainfluenzae. In baby 19, Enterococcus faecium and Enterobacter
cloacae were the most active organisms in day 12 while Enterobacter cloacae and Klebsiella
oxytoca comprised of the largest proportion of the metaproteome in days 16, 20 and 31. In day
26, the pattern was completely different from other samples, probably resulting from the use of
antibiotics. Until day 56, Clostridium II accounted for 30% of the community proteome but its
reads only comprised of less than 5% of the community. In baby 21, apparent difference between
cell abundance and activity was observed for Propionibacterium in day 13, whose proteome was
dominant but proportion of genome abundance was only 15%. For rest samples, Enterobacter
cloacae and Klebsiella oxytoca were most active organisms, which were consistent with the
relative abundance shown in genomic information. Baby 23 was colonized with most complex
microbiome among four infants. The metaproteome of baby 23 was dominated by Klebsiella
pneumoniae in days 15, 18 and 21 and shifted to Bifidobacterium breve in days 34 and 56.

6.5 Main microbial functionality in infant gut microbiome
As discussed above, the microbial composition and proportions not only vary
dramatically during the early colonization phase but also can be remarkably different between
infants, and therefore, comparing abundances of identified proteins across samples is less trivial.
Hence, we employed the strategy of annotating identified proteins by orthologous groups to
make comparisons between samples possible. By using KEGG orthological database,
annotations were obtained for over 80% of identified proteins, with 2236, 2071, 2029 and 2230
KOs assigned for baby 3, 19, 21 and 23 respectively (Figure 6.6). Among all annotated KOs,
1468 KOs (larger than 65%) were commonly identified in four infants and 111 KOs were
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Figure 6.6. Venn diagram of assigned KOs in four infants. A total number of 2236, 2071, 2029
and 2230 KOs were assigned for infants 3, 19, 21 and 23 respectively.
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commonly detected in all 30 fecal samples. Mapping these 1468 common KOs on KEGG
pathways highlighted pathways specific to gut microbiome, including core central metabolisms
of carbohydrates, lipid, nucleotides and amino acid, LPS biosynthetic process and cobalamin
production. These pathways represented the functional core metabolism in the infant gut (Figure
6.7). In addition, many high abundance proteins with important roles were also identified, such
as ATP synthase involved in the oxidative phosphorylation, chaperonin GroEL mediating the
protein folding, PTS-glucose/fructose-specific component transporting sugars into bacterial cells,
RNA polymerase regulating transcription, and peroxiredoxin and superoxide dismutase
defending against the oxidative damage. We also examined the pathways identified in all 30
samples, (blue lines shown in Figure 6.7), which further emphasized the importance of
generating energy (especially central carbon metabolism) in the microbial metabolism.

6.5 Characterization of temporal and inter-individual differences in microbial functions
The main microbial functionalities described above as well as details of longitudinal
microbial functions discussed in Chapter 5 clearly depicted characteristics essential and specific
to the infant gut microbiome. To identify temporal and individual differences in these core
functions, we employed Blast2GO platform to annotate all identified microbial proteins with GO
terms, as GO has a high annotation coverage and therefore provides functional characterization
with different levels of resolution. Approximately 88% of identified proteins (6540/7390 in baby
19, 5619/6347 in baby 21, and 9130/10322 in baby 23) were annotated with at least one GO term.
At a low resolution, major GO term distributions remained stable across infants (similar patterns
as seen in Figure 5.7), with metabolic process including carbohydrate, lipid, protein metabolism,
localization, response to stimulus and methylation among the top 20 terms. Hence, we next
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Figure 6.7. KEGG pathways mapping of common microbial KOs. 1468 common microbial KOs assigned in four infants were mapped
onto KEGG pathways (shown in highlighted lines), among which 111 KOs detected in all samples were highlighted in blue.
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examined the functional differences in a more detailed level consisting of 18 major biological
processes, such as translation, aerobic/anaerobic respiration, SCFA metabolic process,
chemotaxis and et al as listed in Figure 6.8. In general, all these gut microbiome functions were
developed in four infants at certain time points and there was a rapid increase in functionalities
during the early time course, but later, these functions fluctuated over time (Figure 6.8 upper
panel) as a result of all possible factors, for example environment, diet and health status.
For the infant 3, we noticed a great increase in day 28 and 78 for functions related to
pathogenesis, chemotaxis, LPS biosynthesis, response to oxidative stress and biofilm formation,
suggesting a possible bacterial infection. Anaerobic respiration and SCFA were also increased in
days 28 and 78 whereas vitamin production was relatively abundant in the middle time course.
For the infant 19, we observed that most functionalities were decreased for days 12, 16 and 26
due to very low complexity and number of proteins identified. However, cobalamin production
was increased in day 38 whereas pathogenesis and SCFA metabolic process were increased in
day 56. In day 56, a high abundance of autotransporter adhesion was detected. Autotransporter
adhensins are outer membrane proteins of Gram-negative bacteria that are crucial for bacteria to
infect host cells via cell adhesion [205]. Also, an increasing abundance of key enzymes (butyrate
kinase and phosphate butyryltransferase) involved in the production of butyrate were identified,
contributing to the production of SCFA. As compared to infants 3 and 19, variations of functions
in infants 21 and 23 were relatively smaller. Some interesting findings included highly increased
pathogenesis in day 13 of infant 21 with abundant autotransporter adhesins detected and
increased fermentation in days 34 and 50 of infant 23. In total, the gut microbiome exhibit
temporal variations in biological activities described here and the variation patterns were largely
different among infants.
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Figure 6.8. Temporal and inter-individual differences of major microbial functions. Variations of
18 GO terms were analyzed for four infants (separated in four panels) over time. Spectral counts
were summed up for all proteins involved in one GO term and z-score of each GO term was
calculated and plotted. Every dot in the figure represented the z-score of a GO term characterized
in a sample from an infant. A trend showing summed spectral counts of all 18 GO terms for a
sample was displayed on the upper panel of the figure.
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Besides the above major functions, we also compared all KOs assigned among four
infants to visualize the significantly differential expressed functionalities. Among total 2929 KOs,
we identified 973 KOs were significantly different between infants and top 100 significant KOs
were plotted in the heatmap shown in Figure 6.9. A total of 7 clusters were assigned, according
to the similar expression pattern of proteins. Interestingly, proteins in Cluster I were mainly
abundant in the infant 21, including proteins involved in biosynthesis of siderophore group
nonribosomal peptides and CRISPR system cascade. Siderophores are small, high iron affinity
molecules secreted by microbial cells into the environment to scavenge for iron. Enzymes
responsible for the synthesis of siderophores, for example 2,3-dihydro-2,3-dihydroxybenzoate
dehydrogenase (entA), bifunctional isochorismate lyase / aryl carrier protein (entB) and
nonribosomal peptide synthetase (dhbF) were found only expressed in the infant 21. Several
studies have demonstrated the role of siderophores for the survival of pathogenic bacteria and the
development of virulence [206]. The activated siderophore production pathway may be
indicative of bacterial pathogenesis in the competition of irons with the host. We also identified
two CRISPR-associated proteins Cse 4 and Cas 5 in this cluster, suggesting a possible bacterial
defense against invaders. CRISPR/Cas system is a prokaryotic defense mechanism found in
bacteria that provides microorganisms immunity against invading genetic elements, for example,
phages and plasmids [207].
In Cluster II, we detected proteins mainly abundant in the infant 23, including ABC
transporter proteins transporting lactose and other sugars, L-fuconate dehydratase participating in
the fructose metabolism, alpha-L-fucosidase 2 aiding in the degradation of fucosylated glycan
and xylulose-5-phosphate/fructose-6-phosphate phosphoketolase playing key roles in the pentose
phosphate pathway. All these identified proteins belonged to the genus Bifidobacterium and
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Infant #19

Infant #3

Infant #21

Infant #23

Figure. 6.9. Most significantly differentially expressed KOs among infants. KO abundance was
determined by summing up spectral counts of all proteins assigned in a KO and normalized
based on scaling factors for library sizes (edgeR). Significance testing for differential expression
was performed using a negative binomial generalized linear model (GLM) and ANOVA like
analysis in edge R package. Top 100 significantly differentially KOs were hierarchically
clustered based on z-score of log-counts-per-million (log2 counts-per-million).
.
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participated in the carbohydrate utilization. In particular, fermenting carbohydrates via a
phosphoketolase pathway is a unique process in the Bifidobacterium bacteria [208]. The
microbiome in the infant 23 may utilize the carbohydrates via pathways different from other
infants.
In Cluster III, V and VI, we identified proteins depleted in the infant 3. An interesting
finding was that all enzymes (ascorbate-specific PTS transporting system, L-ribulose-5phosphate 4-epimerase, 3-dehydro-L-gulonate-6-phosphate decarboxylase, and L-ribulose-5phosphate 3-epimerase) involved in the ascorbate degradation [209] were identified in infants
other than the infant 3, suggesting that the microbiomes from those three infants can use the
ascorbate as the carbon source under the anaerobic condition.

6.6 Comparison of human proteins among multiple infants
Our developed approach not only allowed the monitoring of microbial functionalities, but
also enabled the simultaneous analysis of human host functions. In total, 3250, 2268, 742, and
1319 human proteins were identified in infants #3, #19, #21 and #23 respectively. Venn diagram
showed that 547 proteins were commonly identified in all infants (Figure 6.10). Mapping these
common proteins onto the KEGG pathway and GO terms highlighted biological processes
responsible for energy generation, including carbohydrate metabolism (mainly glycolysis, TCA
cycle), energy metabolism (mainly oxidative phosphorylation) and lipid metabolism (mainly
fatty acid degradation) (Figure 6.11). These common proteins also included a number of immune
defense proteins, for example, S100 calcium binding protein A8/A9, complement component
3/5/9, lactotransferrin, peroxiredoxin 1/2, serpin peptidase inhibitor which are important in
providing the interaction between the human host and gut microbes [94]. We also identified
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Figure 6.10. Venn diagram of human proteins among infants.

162

Figure 6.11. KEGG pathways mapping of common human proteins. 547 human proteins commonly identified in four infants were
mapped onto KEGG pathways (shown in highlighted lines), among which 38 proteins detected in all samples were highlighted in blue.
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trefoil factor 3 (TFF3) in all infants but with relatively low abundance (~ 10 spectral counts).
TFF3 is typically secreted abundantly at the mucosal surface by goblet cells in the intestine and
plays important roles in the maintenance and repair of the intestinal mucosal barrier. Deficiency
of TFF3 has been suggested in premature infants and the pathogenesis of NEC [210]. In addition,
proteins participating in the host intestinal mucus layer development were also identified in all
infants, including MUC2 mucin, CLCA1 and FCGBP [210]. The intestinal mucus layer play
critical roles in providing a barrier preventing bacterial invasion into the epithelium and
researchers have suggested that the composition of the gut microbiota can shape the mucus
structure [211]. Another important component in preventing the intestinal permeability is the
production of tight junctions between epithelial cells, for example zonula occluding proteins ZO1, ZO-2, and ZO-3, occluding, and the claudin family [212]. However, we only detected low
abundance (less than 5 spectral counts) ZO-1, ZO-2, ZO-3, claudin-3 and claudin-7 proteins in
one or two samples among the total 30 samples, suggesting the immature development of tight
junctions for these premature infants.
We further dissected the expression pattern of human proteins across four infants over the
time course. Identified human proteins were hierarchically clustered using protein abundance and
four clusters were determined (Figure 6.12). GO enrichment using David Bioinformatics
Resources revealed enrichment of fatty acid beta-oxidation, generation of precursor metabolites
and energy, glucose metabolic process, oxidative phosphorylation, cation transport, protein
transport, regulation of apoptosis, and cytoskeleton organization in Cluster I and II. We noticed
that most proteins in these two clusters were generally depleted in samples collected from later
time points (days 78, 86 of infant 3, day 56 of infant 19, and days 34 and 50 of infant 23),
indicating essential roles of above mentioned pathways in the early development of infant
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Figure 6.12. Hierarchical clustering of human proteins among infants. Identified human proteins
were filtered with the threshold of copy per million (cpm) > 100 in at least half samples (edgeR).
Protein abundance was normalized using trimmed mean of m-values (TMM) based on scaling
factors for library sizes. Heatmap was generated using moderated log-counts-per-million (log2
counts-per-million).
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intestine. In Cluster III and IV, we observed proteins almost identified across samples with
enriched GO terms including defense response, response to extracellular/endogenous stimulus
and anti-apoptosis. Bacterial colonization during infancy plays a critical role in the maturation of
host immune system and the establishment of life-time tolerance to the commensals [213].
Colonized bacteria activate the innate immune pathways in epithelial cells and induce human
immune maturation and tolerance. On the other hand, the host produces intestinal barrier and
immune factors to control activities of the microbiome. Therefore, a constantly tuned immune
response in the host gut is essential to keep the balance between the microbiome and human host.

6.7 Discussion and conclusions
In this study, we employed a metaproteomic pipeline to characterize the temporal
microbial functions and interactions with human host in three more premature infant gut (in
addition to the infant studied in the last chapter), aiming to examine the inter-individual
variations among multiple infants.
An obviously increasing complexity/population of gut microbial community was
observed over the time course in two infants but the trend was not clear in the other two,
suggesting that the degree of infant gut microbiome diversity/density could be different despite
the same/close day of life (DOL). Thus, it might be possible that the microbiomes of the latter
two infants developed quickly and thus already achieved a moderate abundance of microbial
population at the time when we collected the samples.
We identified temporal variations in both microbial and human proteins. When only
looking at microbial proteins, in general, samples from adjacent sampling days were more
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similar unless there was a drastic change, for example the complete different microbial
community composition detected in day 26 of infant 19, probably relating to the antibiotics use.
However, human host proteins did not respond in the same manor but still separated early time
points from late time points in all infants with the exception of infant 21. Interestingly, very
small differences were detected in human proteins of infant 21 although differences were
observed in microbial proteins. We suspect that the low complexity of microbiome in this infant
may contribute to the relatively stable expression of human proteins as a result of less diverse
host-microbial interactions.
Characteristics essential and specific to the infant gut microbiome were characterized
among infants, including all central energy metabolism in carbohydrates, lipid, nucleotides and
amino acids as well as microbiome-specific processes such as vitamin synthesis, SCFA
production and LPS biosynthesis. However, these processes can be established at different time
of the colonization and varied greatly over time in a personalized pattern with impacting factors
unclear. In addition to these core metabolisms, several pathways/proteins were found unique to a
particular infant, for example the siderophore production in the infant 21 and the
phosphoketolase pathway in the infant 23, indicating types of unique microbial functions. Core
metabolisms were also examined in the human host, which mainly involved in energy production,
epithelial barrier construction and immune response. However, trefoil factor 3 and tight junction
proteins were detected with low abundance or not detected, suggesting that the epithelial barrier
was immature or still under development in these premature infants. In addition, proteins
participating in the host immunity were constantly abundant over time as essential components
in the balance and control of gut microbiome and the maturation of human immune system.

168

The infants in this study are different in many aspects including delivery mode, feeding
type, the use of antibiotics and health status, all of which can have influenced microbial
colonization. Thus, more proteomic data collected from premature infants between groups, e.g.
healthy versus diseased (NEC), may help the determination of the proteomic baseline for healthy
individuals and the investigation of proteomic differences between healthy and diseased groups,
which are important questions required to be answered for our better understanding of NEC
onset.

.
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CHAPTER 7
Conclusions and future perspectives

7.1 Conclusions from the development and application of metaproteomics approach in the
characterization of infant gut microbiome
The advent of whole-genome sequencing technology has largely changed microbiology
from analyzing cultured isolates to discovering a variety of environmental communities and
understanding their interactions and responses to the environment. Our understandings of
microbial community functionalities are further enhanced by the continuous development in
proteomic platforms including the improved analytical capabilities with high speed, resolution
and accuracy mass spectrometers and the development of available peptide/protein identification
algorithms and informatics pipelines. The human gut microbiome is the most studied ecosystem
due to its critical role in human physiology and association with a number of inflammatory and
metabolic disorders. The beginning of the intestinal community occurs during infancy and
develops as human body grows and develops. The establishment process can be shaped by many
factors and have an impact on infants’ health and health later in life potentially [89]. Despite
increasing studies have been conducted on infants gut microbiome and revealed microbial
composition changes associated with early life events, the characterization of functional shift at
the protein level is much less addressed, which is required to answer “what does happen”.
With regard to the sample preparation, a double filtering strategy aiming in the in-depth
measurement of microbial proteins was designed in Chapter 3 as abundant human proteins
preventing the detection of low abundance microbial proteins. We have demonstrated that our
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approach facilitated greater than 50% increase in the overall peptide/protein identifications for
two infant fecal microbiomes. Indeed, the depth of both microbial and human protein
measurement was improved as a result of removing those abundant human proteins. In this study,
we also addressed that less than 30% of total collected spectra were assigned as peptides and a
large proportion of unassigned spectra were assigned with high quality scores, highlighting the
importance of metagenome completeness and the need for new data interpretation solutions, for
example de novo sequencing. Although functional characterization of identified proteins wasn’t
the focus of this study, the employment of COG categories in the analysis further demonstrated
that the improved depth in microbial proteins revealed newly identified functional categories.
Not only the sample preparation, but also the instrumental and informatics methodologies
affect the success of metaprotomics studies, and therefore careful considerations are need and
have been discussed in Chapter 4. We demonstrated that optimized data acquisition settings by
enabling isotopic precursor selection improved the depth and accuracy of proteome measurement.
We summarized available approaches for the construction of a metagenome database and
illustrated how the quality and complexity of the metagenome impacted confident protein
identifications. As the complexity of ecosystem increased, the differentiation between true and
false identifications became difficult and thus the threshold for confident identifications largely
increased, which might suggest the need for new solutions other than the target-decoy search
estimating FDR strategy, to efficiently determine the confidence for very large database.
Redundancy of the metaproteomic data is one difficulty hindering the unambiguous protein
inference in the metaproteomic analysis. One efficient way to alleviate this problem is to cluster
proteins based on sequence homology. To apply the clustering approach in the infant gut
metaproteomics, we evaluated the degree of redundancy for both human and microbiome
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databases and determined the appropriate similarity threshold used for protein clustering, via
balancing the tradeoff between the protein ambiguity and resolution. Considering the important
role of protein structure in the determination of protein function, the sequence similarity is only
partly reliable to group proteins with similar functions. Therefore, future clustering strategies
need to be developed based on information other than protein sequences, for example protein
domains/models. Lastly, we compared two label free quantification methods (spectral counting
and MIT) on the infant gut metaproteome and found a high correlation between the two methods
despite respective advantages and disadvantages.
With the pipeline established in above two chapters, we measured and investigated
longitudinal microbial functionalities and interactions with the human host in a healthy
premature infant gut. We demonstrated the feasibility and robustness of our metaproteomic
approach in 12 infant fecal samples by detecting a total of 9318 microbial and 3250 human
protein groups and revealing rapid microbial colonization as well as changes in the relative
abundance of human and microbial proteins. Also observed in other proteomics studies,
community activities were not perfectly consistent with community abundances in this study.
Although the main goal of metaproteomics is not to identify the presence of microbial organisms
but rather their functions, assigning proteins to specific species was helpful in the assessment of
common and dominant microbial metabolisms. KEGG mapping of all identified proteins
revealed metabolic pathways/activities operated both commonly and separately by human host
and gut microbiome. In particular, pathways involving in the epithelial barrier establishment and
immune responses were exclusively detected in human proteomes whereas vitamin and SCFA
production were only seen in the microbiome, which are essential characteristics also shown in
the human adult gut microbiome. Based on protein expression patterns of microbiome over the
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time course, we identified four clusters/phases revealing functional shifts involving in glycolytic
process, translation, aerobic/anaerobic respiration, vitamin synthesis, hexose catabolic process,
LPS biosynthesis, PTS system, biofilm formation, and responses to various stimuli. At the same
time, functions of human proteomes were monitored and mainly associated with immune defense
and inflammatory response. Proteins associated with digestion, antibacterial activity, mucosal
barrier proteins and innate immune responses were found among the most abundant proteins.
While a variety of factors can influence the microbial colonization during infancy, it is
also interesting to investigate the commonalities and variations between individuals. In addition
to the infant studied in the last chapter, we further measured gut metaproteomes from three more
premature infants, aiming to investigating the differences of functional development among
multiple infants. With the metaproteomic pipeline previously developed, we achieved in-depth
metaproteomic measurements in all three infants with a total of 9666, 7092, and 11649 protein
groups detected, which also revealed the intra- and inter- variations in the number of identified
human versus microbial proteins as well as their relative abundances. Core metabolic pathways
were identified in both human and microbial proteins, representing the establishment of the
mutualistic relationship between the microbiome and human host during infancy, in which gut
bacteria processed essential vitamins and activated host immune response while human host
initiated the mucosal construction and immune defense. However, unlike human adult, infant gut
exhibit large temporal variations in the abundance of these core metabolisms as a result of infant
gut microbiome ecosystem being immature and unstable. Although most functionalities were
shared among infants, pathways specific to particular infants were also identified, which might
be strongly related to factors that were different among infants. Nevertheless, more proteomic
data and significant number of individuals are needed to further address these observations.
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7.2 Remaining challenges and future perspectives for human gut metaproteome research
The metaproteomic approach has emerged as an indispensable tool in order to explore
global biological functions of complex ecosystems. The metaproteomic approach developed in
this dissertation monitored both human and microbial proteins over time and revealed host and
microbiome specific metabolic activities as well as temporal and inter-individual variations in
these functions. Nevertheless, we are still at the beginning of understanding the gut microbiome
by employing “omics” approaches generating large amounts of complex datasets, especially for
metaproteomics. Metaproteomics is behind metagenomics in terms of the number of analyzed
samples and available informatics platforms. However, progress in advanced metaproteomics
methodologies is fast and the throughput of metaproteomic measurement is increasing. In this
section, we will discuss remaining questions and future directions in the gut metaproteomics
research.
7.2.1 The need for better assembled and annotated metagenomes
Assembling a high-quality metagenome is a major hurdle for extensive protein
identifications in metaproteomics experiments, as current identification strategy and algorithm
mainly rely on the completeness and accuracy of protein database predicted from the
metagenome. Due to the complexity of gut microbiome, constructions of metagenomes from the
human gut microbiome are commonly incomplete. In this dissertation, we have identified a large
amount of unassigned high quality spectra which could be peptides belonging to proteins that are
not included in the constructed database. Therefore, limitations in protein identifications enforce
the need for new sequencing technologies and advanced assembly algorithms providing more
reliable and complete metagenomes.
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Functional annotation of proteins through orthologous protein database COG or KO, or
GO database provide a broad overview of functions in the complex gut ecosystem and enable the
functional comparison between microbial communities with different composition. Nevertheless,
these databases have limitations in the sequence coverage and may not be specific to the human
intestinal microbiome. Therefore, further improvements in the metagenome annotation will
require a higher sequence coverage database and more preferable, an annotation database
specific for the human gut microbiome.
7.2.2 The need for high-throughput measurement campaigns
The increasing genomic information of human genomes as well as the intestinal
microbiomes has greatly improved our knowledge of the variety and complexity in the human
gut microbiome. Large-scale comparative analyses of metagenomes have begun to uncover a
large number of factors impacting human host physiology and shaping the composition and
structure of microbes in the gut. Metaproteomes analyzed in this dissertation and also other
related studies have also revealed that every individual harbors a unique/personalized gut
metaproteome and their functions can vary temporally. In particular, dramatic variation has been
observed in infants during early microbial colonization. Therefore, in order to identify all
possible influencing factors and further determine which factor leading to what changes and if so,
to what extent, future large-scale comparative metaproteomic investigations would be required to
conduct longitudinal studies and analyze sufficient number of samples. This is critical for
researchers to acknowledge what functional characteristics are essential for the definition of “a
healthy microbiota” and further to determine functional differences between diseased and
healthy individuals, specifically those associated with diseases. Therefore, there is a strong need
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for significant improvements in throughput of mass spectrometry-based metaproteomic
approaches in the coming years.
Recently, multiplexing quantification technologies using isobaric chemical tags such as
TMT and iTRAQ, have allowed increasing throughput of proteomic experiments without
increasing analysis complexity. Paulo et al. has demonstrated the feasibility of using 10-plex
TMT to compare 10 different samples in a single mass spectrometric experiment [214].
Theoretically, multiplexing approach, for example 10-plex, is 10 times faster than the label free
method and the sensitivity can be increased since multiple samples are combined. However, to
achieve comparable depth of measurement as single one-sample experiment is not trivial and the
technology still face its own issues, for example co-fragmented containing ions and co-alesced
reporter ions. Future efforts to improve the multiplexing technology, particularly the
optimization and robustness for complex fecal samples are needed and will advance gut
metapreoteomics investigations in a high throughput manner.
This and related work has ignited a flurry of metaproteomic research on the human
microbiome. Continued improvements in sample preparation methods, high performance mass
spectrometers and bioinformatics platforms will allow thorough insights into biological
information of the human-microbiome ecosystem. We anticipate that in the next five to ten years
that we may be able to harness the power of our knowledge to guide the use of pre- and probiotics nurturing a healthy microbiota and interventions that allow for prevention and cure for
microbiome-mediated inflammatory and immune diseases.
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